provider: cyberian
model: deep-research
cached: true
start_time: '2026-01-23T16:52:44.262968'
end_time: '2026-01-23T16:52:44.264797'
duration_seconds: 0.0
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: PLD3
gene_symbol: PLD3
uniprot_accession: Q8IV08
protein_description: 'RecName: Full=5''-3'' exonuclease PLD3 {ECO:0000305}; EC=3.1.16.1
{ECO:0000269|PubMed:30111894, ECO:0000269|PubMed:30312375}; AltName: Full=(S,S)-bis(monoacylglycero)phosphate
synthase PLD3 {ECO:0000305|PubMed:39423811}; EC=3.1.4.- {ECO:0000269|PubMed:39423811};
AltName: Full=HindIII K4L homolog; AltName: Full=Hu-K4 {ECO:0000303|PubMed:15794758};
AltName: Full=Phospholipase D3;'
gene_info: Name=PLD3 {ECO:0000303|PubMed:26411346, ECO:0000312|HGNC:HGNC:17158};
organism_full: Homo sapiens (Human).
protein_family: Belongs to the phospholipase D family. .
protein_domains: Diverse_PLD-related. (IPR050874); PLDc_3. (IPR032803); PLipase_D/transphosphatidylase.
(IPR001736); PLDc_3 (PF13918)
provider_config:
timeout: 1800
max_retries: 3
parameters:
allowed_domains: []
agent_type: claude
port: 3284
skip_permissions: true
citation_count: 15

Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

• UniProt Accession: Q8IV08
• Protein Description: RecName: Full=5'-3' exonuclease PLD3 {ECO:0000305}; EC=3.1.16.1 {ECO:0000269|PubMed:30111894, ECO:0000269|PubMed:30312375}; AltName: Full=(S,S)-bis(monoacylglycero)phosphate synthase PLD3 {ECO:0000305|PubMed:39423811}; EC=3.1.4.- {ECO:0000269|PubMed:39423811}; AltName: Full=HindIII K4L homolog; AltName: Full=Hu-K4 {ECO:0000303|PubMed:15794758}; AltName: Full=Phospholipase D3;
• Gene Information: Name=PLD3 {ECO:0000303|PubMed:26411346, ECO:0000312|HGNC:HGNC:17158};
• Organism (full): Homo sapiens (Human).
• Protein Family: Belongs to the phospholipase D family. .
• Key Domains: Diverse_PLD-related. (IPR050874); PLDc_3. (IPR032803); PLipase_D/transphosphatidylase. (IPR001736); PLDc_3 (PF13918)

MANDATORY VERIFICATION STEPS:

1. Check if the gene symbol "PLD3" matches the protein description above
2. Verify the organism is correct: Homo sapiens (Human).
3. Check if protein family/domains align with what you find in literature
4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'PLD3' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene PLD3 (gene ID: PLD3, UniProt: Q8IV08) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

PLD3 (Phospholipase D3): A Comprehensive Review

Introduction

Phospholipase D3 (PLD3), encoded by the PLD3 gene on human chromosome 19q13.2, represents a fascinating case of misleading nomenclature in molecular biology. Despite being assigned to the phospholipase D family based on sequence homology to viral K4L proteins and the presence of characteristic HKD catalytic motifs, PLD3 has been definitively shown to function primarily as a 5'-3' exonuclease rather than a phospholipase[gavin-2018-exonuclease-abstract]. This lysosomal enzyme degrades single-stranded DNA and RNA substrates and was recently discovered to also synthesize bis(monoacylglycero)phosphate (BMP), a critical lysosomal lipid[singh-2024-bmp-abstract]. PLD3 has attracted significant attention due to its genetic association with late-onset Alzheimer's disease[cruchaga-2014-alzheimer-abstract] and spinocerebellar ataxia type 46[nibbeling-2017-sca46-abstract], positioning it at the intersection of nucleic acid metabolism, lipid homeostasis, and neurodegeneration.

The history of PLD3 research spans more than five decades. In 1968, Bernardi and Bernardi purified and characterized an acidic ssDNA-specific 5' DNase from bovine spleen, which they termed "spleen exonuclease"[bernardi-1968-spleen-abstract]. However, the gene encoding this enzyme remained unidentified for 50 years until 2018, when Gavin et al. demonstrated that PLD3 (and its paralogue PLD4) possess 5' exonuclease activity indistinguishable from classical spleen exonuclease and detected PLD3 in commercial preparations of this enzyme[gavin-2018-exonuclease-abstract]. This discovery represented a paradigm shift in understanding PLD3 function, transforming it from a presumed phospholipase of unknown activity into a key regulator of lysosomal nucleic acid metabolism and innate immunity.

The Phospholipase D Family: PLD3 in Context

The mammalian phospholipase D (PLD) family comprises six members (PLD1-PLD6), which share the characteristic HxKxxxxD (HKD) catalytic motif but have diverged substantially in function and localization. PLD1 and PLD2 are the classical cytosolic phospholipases, catalyzing hydrolysis of phosphatidylcholine to generate phosphatidic acid and choline, thereby mediating critical intracellular signaling pathways. These enzymes share approximately 53% sequence homology and require phosphatidylinositol 4,5-bisphosphate (PIP2) as a cofactor. Both contain PX (phox homology) and PH (pleckstrin homology) domains that regulate their membrane association and subcellular dynamics during signal transduction.

In contrast, PLD3 and PLD4 represent a functionally distinct subgroup within the family. While they retain the paired HKD motifs characteristic of the superfamily, they lack the PX and PH domains present in PLD1 and PLD2. More fundamentally, PLD3 and PLD4 function as 5'-to-3' exonucleases rather than phospholipases[gavin-2018-exonuclease-abstract]. These enzymes are glycosylated type II transmembrane proteins that localize to endolysosomes, in contrast to the primarily cytosolic distribution of PLD1 and PLD2. Structural analysis confirms that critical residues required for phospholipase activity are not conserved in PLD3[ishii-2024-structure-abstract], providing a molecular explanation for this functional divergence.

The products of PLD3 and PLD4 nuclease activity also differ from other nucleases in the PLD superfamily. While enzymes such as PLD6 (Zucchini), Nuc, and BfiI generate products with 5'-phosphate and 3'-hydroxyl termini, PLD3 and PLD4 produce fragments with 5'-hydroxyl and 3'-phosphate[gavin-2018-exonuclease-abstract]. This allows them to further process the products of RNase T2 and DNase II, which generate 5'-OH nucleotides, positioning PLD3/4 as terminal degradative enzymes in lysosomal nucleic acid catabolism.

PLD3 and PLD4 exhibit complementary tissue expression patterns. PLD4 is highly expressed in dendritic cells and other myeloid cells, with lower expression in B cells. PLD3 is more broadly expressed, with highest levels in the brain, followed by thymus. In some tissues such as spleen and liver during early development, PLD3 and PLD4 expression levels are comparable and exceed those of PLD1 and PLD2[gavin-2018-exonuclease-abstract].

Tissue Expression and Cellular Distribution

PLD3 exhibits a distinctive tissue expression pattern with notable enrichment in neuroendocrine tissues. According to Human Protein Atlas data, the pituitary gland shows the highest RNA expression levels (672.4 nTPM), classifying PLD3 as "tissue enhanced" for this endocrine organ. Brain regions consistently demonstrate elevated PLD3 levels, particularly the hypothalamus (391.2 nTPM), cerebral cortex (359.4 nTPM), basal ganglia (278 nTPM), and hippocampal formation (261.1 nTPM). This brain-enriched expression pattern is significant given PLD3's association with neurodegenerative diseases.

At the cellular level, PLD3 displays cytoplasmic expression at variable levels in most cell types, with the highest abundance in neuronal cells and immune cells. Within the brain, nearly all cortical neurons, hippocampal pyramidal neurons, and dentate gyrus granule cells express intense PLD3 immunoreactivity, with the protein concentrated in the cytoplasm forming fine granular structures enriched in the soma and proximal neurites[satoh-2014-plaques-abstract]. A subset of pericytes surrounding capillaries also express PLD3. Notably, reactive astrocytes and activated microglia do not express PLD3, even when accumulated around senile plaques in Alzheimer's disease brains[satoh-2014-plaques-abstract].

The subcellular distribution of PLD3 reflects its trafficking pathway and functional roles. While newly synthesized PLD3 can be detected in the endoplasmic reticulum, the mature functional form localizes primarily to lysosomes. Immunohistochemistry in human tissue demonstrates strong colocalization with lysosomal markers including LAMP2, cathepsin B, cathepsin D, and progranulin[nackenoff-2021-lysosomal-abstract]. This lysosomal localization is consistent with PLD3's acidic pH optimum and its role in terminal nucleic acid degradation.

Protein Structure and Domain Organization

Human PLD3 is a 490-amino acid type II transmembrane protein, first characterized in detail by Munck et al. in 2005 under the name Hu-K4[munck-2005-huk4-abstract]. The protein consists of a short N-terminal cytoplasmic tail (residues 1-36), a single transmembrane domain (residues 37-59), and a large C-terminal luminal domain (residues 60-490) that contains the two characteristic phospholipase D superfamily HKD motifs[roske-2024-structure-abstract]. The type II topology ensures that the catalytically active C-terminal domain resides within the lumen of the endolysosomal system.

Recent crystallographic studies have provided detailed structural insights into PLD3. Roske et al. determined the structure of the human PLD3 luminal domain at 1.9 Å resolution, revealing a typical phospholipase fold organized as a bilobal architecture[roske-2024-structure-abstract]. Ishii et al. independently solved the structure at 2.3 Å resolution, confirming the bilobal organization with the catalytic site positioned between the lobes[ishii-2024-structure-abstract]. A striking finding from both structural studies is that while PLD3 retains the overall fold of the phospholipase D superfamily, the critical residues required for phospholipase activity are either not conserved or entirely absent[ishii-2024-structure-abstract]. This structural evidence definitively explains why PLD3 lacks phospholipase activity despite belonging to this enzyme family.

PLD3 forms homodimers through a newly identified dimerization interface involving helices α10 and α11, creating an interface area of approximately 1042 Ų[roske-2024-structure-abstract]. This dimeric architecture positions the two N-termini (where the transmembrane domains connect in the full-length protein) pointing in the same direction, enabling proper membrane anchoring. Each dimer contains two independent catalytic centers, doubling the enzyme's nuclease capacity. The active site is formed by residues from two HKD motifs: H201, K203, and D208 from the first motif oppose H416, K418, and E423 from the second motif at the pseudo-dimer interface[roske-2024-structure-abstract].

Enzymatic Activities and Catalytic Mechanism

Exonuclease Activity

The primary enzymatic function of PLD3 is as a 5'-to-3' exonuclease that hydrolyzes the phosphodiester bonds of single-stranded DNA and RNA substrates[gavin-2018-exonuclease-abstract]. The enzyme cleaves nucleotides sequentially from the 5' end, releasing nucleoside 3'-monophosphates as products. PLD3 exhibits several key characteristics that define its substrate specificity: it requires unphosphorylated 5' ends, lacks endonuclease activity, and operates optimally at acidic pH (below 6) consistent with its endolysosomal localization[gavin-2018-exonuclease-abstract]. The enzyme can still function at neutral pH 7, albeit with reduced efficiency. Importantly, PLD3 cleaves single-stranded RNA with similar efficiency to ssDNA[gavin-2021-dna-rna-abstract].

The catalytic mechanism of PLD3 proceeds via a classical phospholipase D superfamily ping-pong reaction involving a covalent phosphohistidine intermediate[roske-2024-structure-abstract]. In the first step, H416 (using PLD3 numbering) attacks the phosphodiester bond of the substrate, forming a phospho-histidine intermediate while H201 protonates the leaving 5'-OH nucleic acid fragment. In the second step, the now-deprotonated H201 accepts a proton from an attacking water molecule, which hydrolyzes the phospho-histidine intermediate to release the nucleoside 3'-monophosphate product. Structural snapshots of PLD4, a close paralogue, captured intermediate states that confirmed this mechanism and unexpectedly revealed phosphatase activity capable of removing 5'-phosphate groups via the same phosphohistidine intermediate.

The crystal structure of PLD3 in complex with ssDNA reveals key substrate-binding features[roske-2024-structure-abstract]. The first 5'-thymidine of the substrate undergoes hydrophobic stacking against Tyr411, with additional stabilization through hydrogen bonding interactions. This binding mode positions the phosphodiester bond appropriately for nucleophilic attack by the catalytic histidine.

BMP Synthase Activity

A remarkable 2024 discovery by Singh et al. revealed that PLD3 (along with PLD4) possesses a second, mechanistically distinct enzymatic activity: the synthesis of (S,S)-bis(monoacylglycero)phosphate (S,S-BMP)[singh-2024-bmp-abstract]. BMP is an abundant and unique lysosomal phospholipid essential for the degradation of lipids, particularly gangliosides. Unlike typical glycerophospholipids that contain glycerol in the R stereo-configuration, lysosomal BMP possesses two chiral glycerol carbons in the S configuration, which protects it from lysosomal degradative enzymes.

How this unusual stereochemistry was achieved had been a 50-year mystery. Singh et al. demonstrated that PLD3 and PLD4 catalyze the critical glycerol stereo-inversion reaction required for S,S-BMP synthesis[singh-2024-bmp-abstract]. Deletion of PLD3 markedly reduced BMP levels in brain tissue (where PLD3 is highly expressed), while PLD4 deletion reduced BMP in spleen (where PLD4 predominates). Loss of either enzyme led to gangliosidosis and lysosomal abnormalities. Critically, disease-associated PLD3 variants (including those linked to Alzheimer's disease and spinocerebellar ataxia) showed diminished BMP synthase activity, suggesting this function may be mechanistically important for neurodegeneration.

Subcellular Localization and Trafficking

PLD3 is a resident lysosomal protein that reaches its destination through an unconventional trafficking pathway[roske-2024-structure-abstract]. The protein is synthesized as an N-glycosylated type II transmembrane protein in the endoplasmic reticulum. Munck et al. initially observed PLD3 localization to the ER when expressed exogenously[munck-2005-huk4-abstract], but subsequent studies clarified that the mature, active form localizes to endolysosomes.

Trafficking to lysosomes depends on the ESCRT (endosomal sorting complex required for transport) machinery, representing an uncommon biosynthetic route for mammalian lysosomal proteins. Upon reaching acidic compartments, PLD3 undergoes proteolytic processing by an as-yet-unidentified protease, releasing the soluble luminal domain[roske-2024-structure-abstract]. Mass spectrometry analysis identified Gln72 as the neo-N-terminus after processing, with this glutamine residue modified to pyroglutamate through spontaneous cyclization, forming a stable N-terminus.

PLD3 also participates in endosomal trafficking beyond its role as a lysosomal enzyme. Mukadam et al. demonstrated that PLD3 co-localizes with amyloid precursor protein (APP) in endosomes and regulates endosomal protein sorting[mukadam-2018-endosome-abstract]. Loss of PLD3 function reduces endosomal tubules, impairs trafficking of multiple membrane proteins, and disrupts the association between sortilin-like receptor 1 (SorL1) and APP. This endosomal sorting function appears distinct from, though potentially related to, PLD3's catalytic activities.

Role in Innate Immunity and Inflammation

A critical physiological function of PLD3 is the negative regulation of nucleic acid-sensing toll-like receptors (TLRs) within the endolysosomal system[gavin-2018-exonuclease-abstract][gavin-2021-dna-rna-abstract]. By degrading single-stranded DNA and RNA that enters lysosomes, PLD3 limits the activation of TLR9 (which recognizes unmethylated CpG DNA) and TLR7 (which recognizes ssRNA). This regulatory function prevents excessive inflammatory responses to endogenous nucleic acids.

The immunological importance of PLD3 became strikingly apparent in knockout mouse studies. While Pld3-/- mice show exaggerated TLR9 responses but are viable, combined Pld3-/-Pld4-/- double knockout mice develop fatal hemophagocytic lymphohistiocytosis (HLH) within the first weeks of life[gavin-2018-exonuclease-abstract]. This severe autoinflammatory condition is characterized by inflammatory liver damage and overproduction of interferon-γ. The accumulation of undegraded nucleic acids constitutively activates both TLR7 and TLR9 signaling through NF-κB[gavin-2021-dna-rna-abstract].

Importantly, PLD3 and PLD4 also regulate cytoplasmic nucleic acid sensing through the cGAS-STING pathway. When lysosomal PLD3 is deficient, accumulated nucleic acids (particularly mitochondrial DNA) can leak to the cytosol, activating STING and triggering type I interferon responses[gavin-2021-dna-rna-abstract][van-acker-2023-mtdna-abstract]. This represents a second tier of innate immune surveillance that becomes aberrantly activated when lysosomal nucleotide catabolism fails.

Connection to Alzheimer's Disease

PLD3 gained prominence in the neurodegeneration field when Cruchaga et al. reported in 2014 that rare coding variants in PLD3 confer risk for late-onset Alzheimer's disease (LOAD)[cruchaga-2014-alzheimer-abstract]. Using whole-exome sequencing in 14 families with LOAD, they identified the V232M variant (rs145999145) that segregated with disease in two independent families and approximately doubled Alzheimer's risk across seven case-control series comprising over 11,000 participants of European descent (OR=2.10, CI=1.47-2.99). PLD3 is highly expressed in brain regions vulnerable to Alzheimer's pathology, including the hippocampus and cortex, and expression is significantly reduced in neurons from AD brains compared to controls[cruchaga-2014-alzheimer-abstract]. However, subsequent replication studies yielded mixed results, and meta-analyses have suggested a more modest effect size (OR approximately 1.53 in larger cohorts).

Accumulation on Neuritic Plaques

A striking neuropathological observation is that PLD3 accumulates on neuritic plaques in Alzheimer's disease brains[satoh-2014-plaques-abstract]. Immunohistochemical studies revealed numerous senile plaques containing swollen dystrophic neurites with intense PLD3 immunoreactivity in the frontal cortex of AD patients. In contrast, PLD3-labeled senile plaques were barely found in age-matched non-AD control brains. This accumulation occurs specifically within neuronal elements; reactive astrocytes and activated microglia at the center and periphery of senile plaques do not express PLD3[satoh-2014-plaques-abstract].

Nackenoff et al. provided additional evidence that PLD3 enrichment occurs within lysosomal accumulations in dystrophic neurites surrounding β-amyloid plaques[nackenoff-2021-lysosomal-abstract]. This pattern was conserved across both human AD brain specimens and the 5xFAD mouse model. Interestingly, higher prefrontal cortex PLD3 expression correlated inversely with β-amyloid plaque burden in the ROS/MAP human cohort, suggesting that PLD3 may have a protective role and that reduced expression contributes to pathology.

Axonal Spheroids and Network Dysfunction

A major 2022 study in Nature by Yuan et al. established a mechanistic link between PLD3 and axonal pathology in AD[yuan-2022-spheroids-abstract]. They demonstrated that amyloid-plaque-associated axonal spheroids significantly disrupt neural network function through conduction blockades, acting as electrical current sinks that progressively impair action potential transmission. PLD3 was found to be highly enriched in these axonal spheroids, and the accumulation of abnormal endolysosomal vesicles correlated with spheroid expansion.

Critically, the study showed that neuronal overexpression of PLD3 triggered endolysosomal vesicle accumulation and spheroid enlargement, worsening axonal conduction blockades. Conversely, PLD3 deletion reduced both endolysosomal vesicles and spheroid size, leading to improved electrical conduction and enhanced neural network function[yuan-2022-spheroids-abstract]. This suggests that targeted modulation of PLD3 or endolysosomal biogenesis could potentially reverse axonal spheroid-induced neural circuit abnormalities independently of amyloid removal.

Mechanistic Pathways

Multiple mechanistic pathways link PLD3 dysfunction to neurodegeneration. Van Acker et al. identified mitochondrial DNA (mtDNA) as a major physiological substrate of PLD3 in neurons[van-acker-2023-mtdna-abstract]. In PLD3-deficient cells, mtDNA accumulates in lysosomes, creating a degradative bottleneck visible as abundant multilamellar bodies containing mitochondrial remnants. This triggers increased PINK1-dependent mitophagy. When mtDNA leaks from compromised lysosomes to the cytosol, it activates cGAS-STING signaling, which upregulates autophagy and induces accumulation of APP C-terminal fragments (APP-CTF) and cholesterol. Notably, STING inhibition largely normalized APP-CTF levels, while APP knockout reduced STING activation, revealing reciprocal regulatory relationships.

The V232M substitution has been shown to impair O-glycosylation at pT271, a post-translational modification essential for normal trafficking and localization, leading to enlarged lysosomes. Nackenoff et al. also found that the V232M variant eliminates phospholipase D enzymatic activity in lysosomes[nackenoff-2021-lysosomal-abstract]. Thus, the AD-associated variant may cause disease through effects on multiple PLD3 functions including enzymatic activity and lysosomal localization.

The 2024 discovery of BMP synthase activity adds another dimension[singh-2024-bmp-abstract]. AD-associated PLD3 variants showed reduced BMP synthesis capacity. Since BMP is essential for ganglioside degradation, impaired PLD3 function could lead to ganglioside accumulation and lysosomal dysfunction, representing a lipid-centric mechanism complementary to the nucleic acid-focused pathways. Additionally, PLD3 was found to interact with progranulin (PGRN), another lysosomal protein implicated in neurodegeneration[satoh-2014-plaques-abstract], suggesting potential functional crosstalk.

Spinocerebellar Ataxia Type 46

In 2017, Nibbeling et al. identified PLD3 as the causative gene for spinocerebellar ataxia type 46 (SCA46), a rare autosomal dominant cerebellar ataxia[nibbeling-2017-sca46-abstract]. In a Dutch family (RF28), they identified the heterozygous L308P mutation (c.923T>C) that segregated with disease in eight affected family members. The mutation affects a highly conserved residue within the second PLD phosphodiesterase domain.

SCA46 presents clinically as adult-onset sensory ataxic neuropathy with cerebellar signs, typically beginning between ages 41-65 years (average 53.5 years)[nibbeling-2017-sca46-abstract]. Patients present with swaying during walking in the dark, with additional features including oculomotor abnormalities, cerebellar dysarthria, and distal sensory impairment in a stocking-and-glove pattern. A case report identified a younger patient with onset at 13 years presenting with sensorineural hearing loss followed by pancerebellar ataxia, optic atrophy, and sensorimotor axonal neuropathy.

The pathogenic mechanism of PLD3 mutations in SCA46 has been debated. Gonzalez et al. generated PLD3 knockout mice that did not develop cerebellar degeneration, challenging a simple loss-of-function model[gonzalez-2018-sca46-abstract]. However, they demonstrated that the L308P mutation causes retention of PLD3 in the endoplasmic reticulum rather than proper lysosomal localization, resulting in loss of exonuclease function at its normal site of action. This suggests that the disease mechanism may involve loss of lysosomal function combined with potential ER stress from protein accumulation, rather than simple haploinsufficiency.

Singh et al. showed that SCA46-associated mutations also reduce BMP synthase activity[singh-2024-bmp-abstract], providing an additional mechanistic link between PLD3 dysfunction and neurodegeneration through impaired lysosomal lipid homeostasis.

Autoimmune and Autoinflammatory Associations

Genome-wide association studies have linked PLD4 (the PLD3 paralogue) to autoimmune diseases including rheumatoid arthritis and systemic sclerosis[gavin-2018-exonuclease-abstract]. While PLD3 itself has not been directly implicated in classical autoimmune conditions in human GWAS, the severe autoinflammatory phenotype of Pld3-/-Pld4-/- mice demonstrates its importance in preventing aberrant immune activation.

More recently, loss-of-function mutations in PLD4 were shown to cause systemic lupus erythematosus (SLE) in humans, highlighting the clinical relevance of defective lysosomal nucleic acid degradation in autoimmunity. Given the functional redundancy between PLD3 and PLD4, variants affecting both paralogues could potentially modify autoimmune disease risk or severity.

The dual regulation of TLR7/TLR9 and STING pathways by PLD3 has therapeutic implications[gavin-2021-dna-rna-abstract]. Understanding how lysosomal nucleases control nucleic acid-driven inflammation may enable new treatments for conditions ranging from systemic autoimmunity to neurodegenerative diseases with inflammatory components.

Open Questions

Several important questions remain regarding PLD3 biology:

1. Relative importance of enzymatic activities: PLD3 possesses both exonuclease and BMP synthase activities. What is the relative contribution of each to its physiological functions and disease associations? Can these activities be genetically or pharmacologically separated?

2. Substrate specificity in vivo: While mtDNA has been identified as a major neuronal substrate, the full spectrum of physiological PLD3 substrates (including specific RNA species) remains incompletely characterized. What determines substrate selectivity in different cell types?

3. Mechanism of neurodegeneration: Multiple pathways connect PLD3 dysfunction to neurodegeneration (nucleic acid accumulation, STING activation, BMP deficiency, endosomal trafficking defects, APP processing, axonal spheroid formation). Which pathway(s) are primary drivers, and do they interact?

4. SCA46 pathogenesis: Why does the L308P mutation cause a predominantly cerebellar phenotype when PLD3 is broadly expressed? What cell-autonomous versus non-cell-autonomous mechanisms contribute?

5. Therapeutic potential: Can PLD3 or its downstream pathways be targeted therapeutically? Would STING inhibitors, BMP supplementation, or modulation of endolysosomal biogenesis benefit patients with PLD3-associated diseases? The finding that PLD3 deletion improves network function in AD models suggests reduction of PLD3 activity might be beneficial in some contexts.

6. Regulatory mechanisms: How is PLD3 expression and activity regulated? What controls its proteolytic processing and activation in lysosomes?

7. Relationship to aging: Does PLD3 function decline with age, potentially contributing to late-onset disease phenotypes?

8. Progranulin interaction: What is the functional significance of PLD3-progranulin interaction in lysosomes, and how does this relate to frontotemporal dementia caused by progranulin mutations?

References

• [bernardi-1968-spleen-abstract]: Bernardi A, Bernardi G. Studies on acid hydrolases. IV. Isolation and characterization of spleen exonuclease. Biochimica et Biophysica Acta. 1968;155(2):360-370. doi: 10.1016/0005-2744(68)90018-5

• [munck-2005-huk4-abstract]: Munck A, Böhm C, Seibel NM, Hashemol Hosseini Z, Hampe W. Hu-K4 is a ubiquitously expressed type 2 transmembrane protein associated with the endoplasmic reticulum. FEBS Journal. 2005 Apr;272(7):1718-26. doi: 10.1111/j.1742-4658.2005.04601.x. PMID: 15794758

• [cruchaga-2014-alzheimer-abstract]: Cruchaga C, Karch CM, Jin SC, et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature. 2014 Jan 23;505(7484):550-4. doi: 10.1038/nature12825. PMID: 24336208; PMCID: PMC4050701

• [satoh-2014-plaques-abstract]: Satoh J, Kino Y, Yamamoto Y, et al. PLD3 is accumulated on neuritic plaques in Alzheimer's disease brains. Alzheimer's Research & Therapy. 2014 Nov 2;6(9):70. doi: 10.1186/s13195-014-0070-5. PMID: 25478031; PMCID: PMC4255636

• [nibbeling-2017-sca46-abstract]: Nibbeling EAR, Duarri A, Verschuuren-Bemelmans CC, et al. Exome sequencing and network analysis identifies shared mechanisms underlying spinocerebellar ataxia. Brain. 2017 Nov 1;140(11):2860-2878. doi: 10.1093/brain/awx251. PMID: 29053787; PMCID: PMC5841203

• [gavin-2018-exonuclease-abstract]: Gavin AL, Huang D, Huber C, et al. PLD3 and PLD4 are single-stranded acid exonucleases that regulate endosomal nucleic-acid sensing. Nature Immunology. 2018 Sep;19(9):942-953. doi: 10.1038/s41590-018-0179-y. PMID: 30111894; PMCID: PMC6105523

• [gonzalez-2018-sca46-abstract]: Gonzalez AC, Stroobants S, Reisdorf P, et al. PLD3 and spinocerebellar ataxia. Brain. 2018 Nov 1;141(11):e78. doi: 10.1093/brain/awy258. PMID: 30312375; PMCID: PMC6202572

• [mukadam-2018-endosome-abstract]: Mukadam AS, Breusegem SY, Seaman MNJ. Analysis of novel endosome-to-Golgi retrieval genes reveals a role for PLD3 in regulating endosomal protein sorting and amyloid precursor protein processing. Cellular and Molecular Life Sciences. 2018 Jul;75(14):2613-2625. doi: 10.1007/s00018-018-2752-9. PMID: 29368044; PMCID: PMC6003983

• [gavin-2021-dna-rna-abstract]: Gavin AL, Huang D, Blane TR, et al. Cleavage of DNA and RNA by PLD3 and PLD4 limits autoinflammatory triggering by multiple sensors. Nature Communications. 2021 Oct 7;12(1):5874. doi: 10.1038/s41467-021-26150-w. PMID: 34620855; PMCID: PMC8497607

• [nackenoff-2021-lysosomal-abstract]: Nackenoff AG, Hohman TJ, Neuner SM, et al. PLD3 is a neuronal lysosomal phospholipase D associated with β-amyloid plaques and cognitive function in Alzheimer's disease. PLOS Genetics. 2021 Apr 8;17(4):e1009406. doi: 10.1371/journal.pgen.1009406. PMID: 33830999; PMCID: PMC8031396

• [yuan-2022-spheroids-abstract]: Yuan P, Zhang M, Tong L, et al. PLD3 affects axonal spheroids and network defects in Alzheimer's disease. Nature. 2022 Dec;612(7939):328-337. doi: 10.1038/s41586-022-05491-6. PMID: 36450991

• [van-acker-2023-mtdna-abstract]: Van Acker ZP, Perdok A, Hellemans R, et al. Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism. Nature Communications. 2023 May 24;14(1):2847. doi: 10.1038/s41467-023-38501-w. PMID: 37225734; PMCID: PMC10209153

• [roske-2024-structure-abstract]: Roske Y, Cappel C, Cremer N, et al. Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5' exonuclease-mediated nucleic acid degradation. Nucleic Acids Research. 2024 Jan 11;52(1):370-384. doi: 10.1093/nar/gkad1114. PMID: 37994783; PMCID: PMC10783504

• [ishii-2024-structure-abstract]: Ishii K, Hermans SJ, Georgopoulou ME, et al. Crystal structure of Alzheimer's disease phospholipase D3 provides a molecular basis for understanding its normal and pathological functions. FEBS Journal. 2024 Dec;291(24):5398-5419. doi: 10.1111/febs.17277. PMID: 39325669; PMCID: PMC11653685

• [singh-2024-bmp-abstract]: Singh S, Dransfeld UE, Ambaw YA, et al. PLD3 and PLD4 synthesize S,S-BMP, a key phospholipid enabling lipid degradation in lysosomes. Cell. 2024 Oct 17;187(21):6820-6834.e18. doi: 10.1016/j.cell.2024.09.020. PMID: 39423811

Citations

1. bernardi-1968-spleen-abstract.md
2. cruchaga-2014-alzheimer-abstract.md
3. gavin-2018-exonuclease-abstract.md
4. gavin-2021-dna-rna-abstract.md
5. gonzalez-2018-sca46-abstract.md
6. ishii-2024-structure-abstract.md
7. mukadam-2018-endosome-abstract.md
8. munck-2005-huk4-abstract.md
9. nackenoff-2021-lysosomal-abstract.md
10. nibbeling-2017-sca46-abstract.md
11. roske-2024-structure-abstract.md
12. satoh-2014-plaques-abstract.md
13. singh-2024-bmp-abstract.md
14. van-acker-2023-mtdna-abstract.md
15. yuan-2022-spheroids-abstract.md

provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-14T17:16:00.287670'
end_time: '2025-12-14T17:22:21.682517'
duration_seconds: 381.39
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: PLD3
gene_symbol: PLD3
uniprot_accession: Q8IV08
protein_description: 'RecName: Full=5''-3'' exonuclease PLD3 {ECO:0000305}; EC=3.1.16.1
{ECO:0000269|PubMed:30111894, ECO:0000269|PubMed:30312375}; AltName: Full=(S,S)-bis(monoacylglycero)phosphate
synthase PLD3 {ECO:0000305|PubMed:39423811}; EC=3.1.4.- {ECO:0000269|PubMed:39423811};
AltName: Full=HindIII K4L homolog; AltName: Full=Hu-K4 {ECO:0000303|PubMed:15794758};
AltName: Full=Phospholipase D3;'
gene_info: Name=PLD3 {ECO:0000303|PubMed:26411346, ECO:0000312|HGNC:HGNC:17158};
organism_full: Homo sapiens (Human).
protein_family: Belongs to the phospholipase D family. .
protein_domains: Diverse_PLD-related. (IPR050874); PLDc_3. (IPR032803); PLipase_D/transphosphatidylase.
(IPR001736); PLDc_3 (PF13918)
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
temperature: 0.1
citation_count: 25

Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

• UniProt Accession: Q8IV08
• Protein Description: RecName: Full=5'-3' exonuclease PLD3 {ECO:0000305}; EC=3.1.16.1 {ECO:0000269|PubMed:30111894, ECO:0000269|PubMed:30312375}; AltName: Full=(S,S)-bis(monoacylglycero)phosphate synthase PLD3 {ECO:0000305|PubMed:39423811}; EC=3.1.4.- {ECO:0000269|PubMed:39423811}; AltName: Full=HindIII K4L homolog; AltName: Full=Hu-K4 {ECO:0000303|PubMed:15794758}; AltName: Full=Phospholipase D3;
• Gene Information: Name=PLD3 {ECO:0000303|PubMed:26411346, ECO:0000312|HGNC:HGNC:17158};
• Organism (full): Homo sapiens (Human).
• Protein Family: Belongs to the phospholipase D family. .
• Key Domains: Diverse_PLD-related. (IPR050874); PLDc_3. (IPR032803); PLipase_D/transphosphatidylase. (IPR001736); PLDc_3 (PF13918)

MANDATORY VERIFICATION STEPS:

1. Check if the gene symbol "PLD3" matches the protein description above
2. Verify the organism is correct: Homo sapiens (Human).
3. Check if protein family/domains align with what you find in literature
4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'PLD3' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene PLD3 (gene ID: PLD3, UniProt: Q8IV08) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

• UniProt Accession: Q8IV08
• Protein Description: RecName: Full=5'-3' exonuclease PLD3 {ECO:0000305}; EC=3.1.16.1 {ECO:0000269|PubMed:30111894, ECO:0000269|PubMed:30312375}; AltName: Full=(S,S)-bis(monoacylglycero)phosphate synthase PLD3 {ECO:0000305|PubMed:39423811}; EC=3.1.4.- {ECO:0000269|PubMed:39423811}; AltName: Full=HindIII K4L homolog; AltName: Full=Hu-K4 {ECO:0000303|PubMed:15794758}; AltName: Full=Phospholipase D3;
• Gene Information: Name=PLD3 {ECO:0000303|PubMed:26411346, ECO:0000312|HGNC:HGNC:17158};
• Organism (full): Homo sapiens (Human).
• Protein Family: Belongs to the phospholipase D family. .
• Key Domains: Diverse_PLD-related. (IPR050874); PLDc_3. (IPR032803); PLipase_D/transphosphatidylase. (IPR001736); PLDc_3 (PF13918)

MANDATORY VERIFICATION STEPS:

1. Check if the gene symbol "PLD3" matches the protein description above
2. Verify the organism is correct: Homo sapiens (Human).
3. Check if protein family/domains align with what you find in literature
4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'PLD3' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene PLD3 (gene ID: PLD3, UniProt: Q8IV08) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research report: Human PLD3 (UniProt Q8IV08)

Identity verification and core definitions
- Gene/protein identity: PLD3 encodes phospholipase D3, a type II single-pass transmembrane glycoprotein localized to the endolysosomal system in human cells. The luminal domain contains the conserved PLD/PLDc (HKD) catalytic motifs characteristic of the phospholipase D superfamily, consistent with UniProt Q8IV08 annotations and “Diverse_PLD-related” domain membership (Homo sapiens). Structural work on human PLD3 confirms the PLD fold and active site architecture in the luminal domain (N-glycosylated), supporting assignment to the PLD family (published Nov 22, 2023; Nucleic Acids Research 2024; URL: https://doi.org/10.1093/nar/gkad1114) (roske2024structuralanalysisof pages 1-2). Complementary structural/biochemical analyses (Structure, Jun 2024; URL: https://doi.org/10.1016/j.str.2024.02.019) demonstrate PLD3 as an endolysosomal 5′ exonuclease with catalysis driven by the HKD histidine, aligning family/domain expectations (yuan2024structuralandmechanistic pages 14-17).

• Primary biochemical activities: Two activities have been reported for human PLD3.
  1) Lysosomal 5′→3′ exonuclease on nucleic acids: Multiple studies show PLD3 cleaves ssDNA and ssRNA from the 5′ end at acidic pH consistent with the lysosome; loss of PLD3 slows luminal nucleic-acid degradation and can potentiate nucleic-acid–sensing pathways (JBC, Jan 2021; URL: https://doi.org/10.1074/jbc.ra120.015867; NAR 2024; Structure 2024) (cappel2021quantificationandcharacterization pages 1-2, roske2024structuralanalysisof pages 1-2, yuan2024structuralandmechanistic pages 14-17).
  2) BMP synthase activity: A 2024 Cell study reports purified PLD3 (and paralog PLD4) synthesize the S,S stereoisomer of bis(monoacylglycero)phosphate (S,S‑BMP) via a transphosphatidylation reaction in lysosomal contexts; PLD3 loss reduces cellular BMP and perturbs lysosomal lipid catabolism (Cell, Nov 2024; URL: https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 7-8).

• Topology, maturation, and modification: PLD3 is synthesized as a type II transmembrane protein and undergoes proteolytic cleavage in lysosomes to generate a soluble luminal enzyme that is catalytically active; dimerization of luminal domains creates two catalytic centers per dimer (NAR 2024; URL: https://doi.org/10.1093/nar/gkad1114) (roske2024structuralanalysisof pages 1-2). A recent preprint indicates PLD3’s soluble form can be AMPylated during neuronal maturation; mapped AMPylation sites modulate processing and activity (bioRxiv, Jan 2025; URL: https://doi.org/10.1101/2025.01.09.632087) (hoffmann2025ampylationregulatespld3 pages 1-3, hoffmann2025ampylationregulatespld3 pages 26-27).

Current understanding: functions, substrates, reactions
- 5′ exonuclease function and substrates: PLD3 preferentially degrades short single-stranded nucleic acids in the lysosomal lumen with an acidic pH optimum around ~6.0; Mg2+/Ca2+ can stimulate activity, and vanadate inhibits activity (IC50 ~10 µM in lysates). A dedicated cell-based assay demonstrated PLD3 as the principal acid 5′ exonuclease in HeLa cells; proteolytic processing is not strictly required for hydrolytic activity in cells (JBC 2021; URL: https://doi.org/10.1074/jbc.ra120.015867) (cappel2021quantificationandcharacterization pages 6-7, cappel2021quantificationandcharacterization pages 1-2). Structural snapshots with bound thymidine product delineate substrate binding and a mechanism consistent with PLD-family catalysis (NAR 2024; URL: https://doi.org/10.1093/nar/gkad1114) (roske2024structuralanalysisof pages 1-2). PLD3 targets include mitochondrial DNA fragments delivered to lysosomes via mitophagy; PLD3 deficiency leads to lysosomal mtDNA accumulation (Nat Commun, May 2023; URL: https://doi.org/10.1038/s41467-023-38501-w) (acker2023phospholipased3degrades pages 9-12).

• S,S‑BMP synthase function and substrates: PLD3 catalyzes S,S‑BMP formation in vitro and in cells, supporting lysosomal lipid degradation. In cells and tissues, PLD3 loss reduces BMP and increases lysosomal cholesterol and gangliosides; exogenous S,S‑BMP can rescue multiple phenotypes, implicating PLD3-dependent BMP in lysosomal lipid homeostasis (Cell 2024; URL: https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 7-8).

Subcellular localization and processing
- Localization: PLD3 localizes to neurons and is enriched in lysosomes/dystrophic neurites around β‑amyloid plaques in AD brain; neuronal PLD3 co-localizes with LAMP2 and cathepsins (PLoS Genetics, Aug 2021; URL: https://doi.org/10.1101/746222) (nackenoff2021pld3isa pages 4-6). PLD3 is a type II transmembrane protein whose luminal domain is proteolytically released to form the active soluble lysosomal enzyme (NAR 2024; URL: https://doi.org/10.1093/nar/gkad1114) (roske2024structuralanalysisof pages 1-2). Preprint data indicate AMPylation of the soluble lysosomal form during neuronal differentiation influences its processing/activity (bioRxiv 2025; URL: https://doi.org/10.1101/2025.01.09.632087) (hoffmann2025ampylationregulatespld3 pages 1-3, hoffmann2025ampylationregulatespld3 pages 26-27).

Pathway context
- Lysosomal nucleic acid catabolism and innate immune signaling: By degrading ssDNA/ssRNA, PLD3 limits activation of endolysosomal nucleic-acid sensors (TLR9/TLR7). In PLD3 deficiency, luminal nucleic acids accumulate and can chronically activate TLRs; leakage of mtDNA into cytosol activates cGAS–STING signaling, driving autophagy, APP-CTF elevation, and cholesterol biosynthesis changes (NAR 2024; URL: https://doi.org/10.1093/nar/gkad1114; Nat Commun 2023; URL: https://doi.org/10.1038/s41467-023-38501-w) (roske2024structuralanalysisof pages 1-2, acker2023phospholipased3degrades pages 9-12).
- Lysosomal lipid metabolism and BMP biogenesis: PLD3 synthesizes S,S‑BMP to support lipid catabolism on intralumenal vesicles; PLD3 loss reduces BMP, increases lysosomal cholesterol, and induces membrane damage signatures (galectin‑3 recruitment); many defects are rescued by exogenous S,S‑BMP, linking key neuronal phenotypes to BMP deficiency (Cell 2024; URL: https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 7-8).
- Lysosomal biogenesis and TFEB/TFE3: Preprint evidence suggests PLD3 regulates TFEB/TFE3 protein turnover via proteasome-mediated degradation, such that PLD3 loss elevates TFEB/TFE3 protein levels and nuclear translocation, amplifying lysosomal biogenesis programs; Aβ exposure augments these changes, consistent with endolysosomal stress (bioRxiv, Sep 2024; URL: https://doi.org/10.1101/2024.09.26.615214) (wang2024phospholipased3regulates pages 1-4, wang2024phospholipased3regulates pages 4-7, wang2024phospholipased3regulates pages 10-12, wang2024phospholipased3regulates pages 24-27, wang2024phospholipased3regulates pages 27-30).

Recent developments and late-breaking evidence (2023–2024 priority)
- Structural mechanism of nucleic-acid cleavage: Two independent structural studies in 2024 delineate PLD3’s luminal architecture, dimerization, and product-bound active site, confirming 5′ exonuclease function and informing the impact of disease-associated variants (Structure, Jun 2024; URL: https://doi.org/10.1016/j.str.2024.02.019; NAR, Nov 2024; URL: https://doi.org/10.1093/nar/gkad1114) (yuan2024structuralandmechanistic pages 14-17, roske2024structuralanalysisof pages 1-2).
- Lysosomal lipid biology: A 2024 Cell study redefines PLD3 as a BMP synthase; neuronal PLD3 loss causes ~70% reduction of BMP in brain with ganglioside accrual; PLD3-deficient cells show ~1.5-fold lysosomal cholesterol increase without changing total cellular cholesterol. S,S‑BMP supplementation reverses lysosomal dysfunction (Cell, Nov 2024; URL: https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 7-8).
- Nucleotide signaling/AD pathways: 2023 work demonstrates PLD3 degrades lysosomal mtDNA; PLD3 deficiency activates cGAS–STING and elevates APP‑CTF, linking lysosomal nucleotide metabolism to AD-relevant proteostasis and lipid remodeling. Pharmacologic STING inhibition rescues APP‑CTF (Nat Commun, May 2023; URL: https://doi.org/10.1038/s41467-023-38501-w) (acker2023phospholipased3degrades pages 9-12).
- Lysosomal biogenesis control: Preprint (2024) implicates PLD3 in TFEB/TFE3 proteostasis: PLD3 loss increases TFEB/TFE3 protein (not mRNA) and nuclear activity, in line with broader lysosomal remodeling seen upon PLD3 deficiency (bioRxiv, Sep 2024; URL: https://doi.org/10.1101/2024.09.26.615214) (wang2024phospholipased3regulates pages 1-4, wang2024phospholipased3regulates pages 4-7, wang2024phospholipased3regulates pages 10-12, wang2024phospholipased3regulates pages 24-27, wang2024phospholipased3regulates pages 27-30).

Disease relevance: Alzheimer’s disease and neurodegeneration
- Genetics/neuropathology: PLD3 variants (e.g., V232M) have been associated with AD risk in some cohorts; in brain tissue, PLD3 is enriched in neuronal lysosomes and dystrophic neurites surrounding plaques, with expression inversely correlated with amyloid burden and cognitive decline. PLD3 activity was detected in isolated lysosomes and was reduced by AD‑associated mutations (PLoS Genetics preprint version, Aug 2021; URL: https://doi.org/10.1101/746222) (nackenoff2021pld3isa pages 4-6).
- Axonal spheroids and network dysfunction: In vivo imaging in AD-model mice shows plaque-associated axonal spheroids (PAASs) act as current sinks causing conduction block. Neuronal Pld3 overexpression enlarged spheroids and worsened conduction; Pld3 deletion reduced endolysosomal vesicles/spheroid size and improved network function, indicating PLD3 as a modulator of neuronal endolysosomal biogenesis and circuit physiology (Nature, Nov 2022; URL: https://doi.org/10.1038/s41586-022-05491-6) (yuan2022pld3affectsaxonal pages 1-2).
- APP-CTF and cholesterol homeostasis via cGAS–STING: PLD3 deficiency causes lysosomal mtDNA accumulation and leakage that activates cGAS–STING, which in turn increases APP‑CTF and alters cholesterol biosynthesis. STING inhibition normalized APP‑CTF, and APP deletion reduced STING activation, demonstrating bidirectional crosstalk (Nat Commun, May 2023; URL: https://doi.org/10.1038/s41467-023-38501-w) (acker2023phospholipased3degrades pages 9-12).

Current applications and real-world implementations
- Mechanistic biomarkers and target engagement: The JBC assay for acidic 5′ exonuclease activity provides a cell-based readout of PLD3/PLD4 function and inhibitor profiling (JBC, Jan 2021; URL: https://doi.org/10.1074/jbc.ra120.015867) (cappel2021quantificationandcharacterization pages 1-2, cappel2021quantificationandcharacterization pages 6-7).
- Therapeutic concepts:
• Modulating innate immune signaling: cGAS–STING inhibitors normalized APP‑CTF in PLD3-deficient models, suggesting a route to mitigate downstream pathology from lysosomal nucleotide accumulation (Nat Commun 2023; URL: https://doi.org/10.1038/s41467-023-38501-w) (acker2023phospholipased3degrades pages 9-12).
• Restoring BMP: Exogenous S,S‑BMP rescued cholesterol accumulation and lysosomal dysfunction in PLD3-deficient cells, nominating BMP supplementation or enhancing endogenous BMP synthesis as a strategy (Cell 2024; URL: https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 7-8).
• Lysosomal biogenesis tuning: Preclinical data suggest PLD3 influences TFEB/TFE3-driven lysosomal programs; modulating this axis may correct endolysosomal stress in neurons (bioRxiv 2024; URL: https://doi.org/10.1101/2024.09.26.615214) (wang2024phospholipased3regulates pages 1-4, wang2024phospholipased3regulates pages 4-7, wang2024phospholipased3regulates pages 10-12, wang2024phospholipased3regulates pages 24-27, wang2024phospholipased3regulates pages 27-30).

Expert opinions and authoritative analyses
- Structural/mechanistic reviews and perspectives in 2024 independently converge that PLD3 is a lysosomal 5′ exonuclease structurally adapted for ssNA binding and cleavage, with disease variants impairing stability/activity (Structure 2024; URL: https://doi.org/10.1016/j.str.2024.02.019; NAR 2024; URL: https://doi.org/10.1093/nar/gkad1114) (yuan2024structuralandmechanistic pages 14-17, roske2024structuralanalysisof pages 1-2).
- The 2024 Cell study reframes PLD3/PLD4 as BMP synthases essential for lysosomal lipid catabolism, providing a unifying model wherein PLD3 couples nucleic-acid clearance and lipid homeostasis via BMP (Cell 2024; URL: https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 7-8).

Key statistics and quantitative data (selected)
- Enzymology (cell-based): pH optimum ~6.0 for PLD3 5′ exonuclease; vanadate IC50 ~10 µM in lysates; EDTA increases activity (~1.4× in lysate; ~5× for recombinant protein); PLD3 shows higher specific acidic 5′ exonuclease activity than PLD4 in HeLa cells (JBC 2021; URL: https://doi.org/10.1074/jbc.ra120.015867) (cappel2021quantificationandcharacterization pages 6-7, cappel2021quantificationandcharacterization pages 1-2).
- Lipidomics/lysosomal metrics: PLD3 loss causes ~70% reduction of BMP in mouse brain, increased lysosomal cholesterol (~1.5×), increased galectin‑3–positive damage, and ganglioside accumulation; exogenous S,S‑BMP reverses phenotypes (Cell 2024; URL: https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 7-8).
- Innate signaling and proteostasis: In PLD3-defective cells, cGAS–STING activation elevates APP‑CTF; STING inhibitor H‑151 reduced APP‑CTF; APP knockout reduced STING activation (Nat Commun 2023; URL: https://doi.org/10.1038/s41467-023-38501-w) (acker2023phospholipased3degrades pages 9-12).
- Neuronal physiology: In AD-model mice, spheroid size correlates with conduction blockade severity; Pld3 deletion reduced endolysosomal vesicle load and spheroid size and improved conduction/network function, while Pld3 overexpression worsened both (Nature 2022; URL: https://doi.org/10.1038/s41586-022-05491-6) (yuan2022pld3affectsaxonal pages 1-2).

Synthesis and current model
- PLD3 is a human lysosomal protein whose luminal domain, released by proteolysis, acts as a 5′→3′ exonuclease on ssDNA/ssRNA and, per 2024 evidence, also catalyzes S,S‑BMP synthesis central to lysosomal lipid catabolism. These functions position PLD3 at the intersection of lysosomal nucleic-acid clearance (limiting TLR7/9 and cGAS–STING activation) and lipid homeostasis (BMP-dependent degradation of lipids and cholesterol mobilization). In neurons, PLD3 levels/activity modulate endolysosomal vesicle burden, axonal spheroid formation, and network conduction. Loss or dysfunction of PLD3 perturbs lysosomal catabolism (nucleic acids and lipids), triggers innate signaling cascades, alters APP‑CTF and cholesterol handling, and elicits compensatory lysosomal biogenesis via TFEB/TFE3—mechanistic axes highly relevant to Alzheimer’s disease pathogenesis (Structure 2024; NAR 2024; Cell 2024; Nat Commun 2023; PLoS Genetics 2021) (yuan2024structuralandmechanistic pages 14-17, roske2024structuralanalysisof pages 1-2, singh2024pld3andpld4 pages 7-8, acker2023phospholipased3degrades pages 9-12, nackenoff2021pld3isa pages 4-6).

Notes on data strength and open questions
- The 5′ exonuclease role is strongly supported by structural biochemistry (2024) and prior enzymology (2021). The BMP synthase role is supported by orthogonal lipid biochemistry/cell and mouse data in Cell (2024). Reconciling dual activities—conditions, regulation, and substrate competition—remains an active area; exogenous S,S‑BMP rescuing mtDNA-related phenotypes argues BMP deficiency is a dominant driver in some contexts (Cell 2024) (singh2024pld3andpld4 pages 7-8). The TFEB/TFE3 regulatory role and AMPylation control are emerging from preprints and warrant peer‑reviewed confirmation (bioRxiv 2024/2025) (wang2024phospholipased3regulates pages 1-4, wang2024phospholipased3regulates pages 4-7, wang2024phospholipased3regulates pages 10-12, wang2024phospholipased3regulates pages 24-27, wang2024phospholipased3regulates pages 27-30, hoffmann2025ampylationregulatespld3 pages 1-3, hoffmann2025ampylationregulatespld3 pages 26-27).

References (URLs and dates)
- Structural/mechanistic nucleases: Structure (Jun 2024) https://doi.org/10.1016/j.str.2024.02.019 (yuan2024structuralandmechanistic pages 14-17); Nucleic Acids Research (online Nov 22, 2023; 2024) https://doi.org/10.1093/nar/gkad1114 (roske2024structuralanalysisof pages 1-2).
- Enzymology assays: Journal of Biological Chemistry (Jan 2021) https://doi.org/10.1074/jbc.ra120.015867 (cappel2021quantificationandcharacterization pages 6-7, cappel2021quantificationandcharacterization pages 1-2).
- Lysosomal lipid biology/BMP: Cell (Nov 2024) https://doi.org/10.1016/j.cell.2024.09.036 (singh2024pld3andpld4 pages 7-8).
- Nucleotide signaling/APP‑CTF/cholesterol: Nature Communications (May 2023) https://doi.org/10.1038/s41467-023-38501-w (acker2023phospholipased3degrades pages 9-12).
- Neuronal localization/AD neuropathology: PLoS Genetics (preprint, Aug 2021) https://doi.org/10.1101/746222 (nackenoff2021pld3isa pages 4-6).
- Axonal spheroids and network physiology: Nature (Nov 2022) https://doi.org/10.1038/s41586-022-05491-6 (yuan2022pld3affectsaxonal pages 1-2).
- TFEB/TFE3 regulation (preprint): bioRxiv (Sep 2024) https://doi.org/10.1101/2024.09.26.615214 (wang2024phospholipased3regulates pages 1-4, wang2024phospholipased3regulates pages 4-7, wang2024phospholipased3regulates pages 10-12, wang2024phospholipased3regulates pages 24-27, wang2024phospholipased3regulates pages 27-30).
- AMPylation and processing (preprint): bioRxiv (Jan 2025) https://doi.org/10.1101/2025.01.09.632087 (hoffmann2025ampylationregulatespld3 pages 1-3, hoffmann2025ampylationregulatespld3 pages 26-27).

References

1. (roske2024structuralanalysisof pages 1-2): Yvette Roske, Cedric Cappel, Nils Cremer, Patrick Hoffmann, Tomas Koudelka, Andreas Tholey, Udo Heinemann, Oliver Daumke, and Markus Damme. Structural analysis of pld3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation. Nucleic Acids Research, 52:370-384, Nov 2024. URL: https://doi.org/10.1093/nar/gkad1114, doi:10.1093/nar/gkad1114. This article has 16 citations and is from a highest quality peer-reviewed journal.

2. (yuan2024structuralandmechanistic pages 14-17): Meng Yuan, Linghang Peng, Deli Huang, Amanda Gavin, Fangkun Luan, Jenny Tran, Ziqi Feng, Xueyong Zhu, Jeanne Matteson, Ian A. Wilson, and David Nemazee. Structural and mechanistic insights into disease-associated endolysosomal exonucleases pld3 and pld4. Structure, 32:766-779.e7, Jun 2024. URL: https://doi.org/10.1016/j.str.2024.02.019, doi:10.1016/j.str.2024.02.019. This article has 11 citations and is from a domain leading peer-reviewed journal.

3. (cappel2021quantificationandcharacterization pages 1-2): Cedric Cappel, Adriana Carolina Gonzalez, and Markus Damme. Quantification and characterization of the 5′ exonuclease activity of the lysosomal nuclease pld3 by a novel cell-based assay. Journal of Biological Chemistry, 296:100152, Jan 2021. URL: https://doi.org/10.1074/jbc.ra120.015867, doi:10.1074/jbc.ra120.015867. This article has 25 citations and is from a domain leading peer-reviewed journal.

4. (singh2024pld3andpld4 pages 7-8): Shubham Singh, Ulrich E. Dransfeld, Yohannes A. Ambaw, Joshua Lopez-Scarim, Robert V. Farese, and Tobias C. Walther. Pld3 and pld4 synthesize s,s-bmp, a key phospholipid enabling lipid degradation in lysosomes. Cell, 187:6820-6834.e24, Nov 2024. URL: https://doi.org/10.1016/j.cell.2024.09.036, doi:10.1016/j.cell.2024.09.036. This article has 37 citations and is from a highest quality peer-reviewed journal.

5. (hoffmann2025ampylationregulatespld3 pages 1-3): Laura Hoffmann, Eva-Maria Eckl, Marleen Bérouti, Michael Pries, Aron Koller, Charlotte Guhl, Ute A. Hellmich, Veit Hornung, Wei Xiang, Lucas T. Jae, and Pavel Kielkowski. Ampylation regulates pld3 processing. bioRxiv, Jan 2025. URL: https://doi.org/10.1101/2025.01.09.632087, doi:10.1101/2025.01.09.632087. This article has 0 citations and is from a poor quality or predatory journal.

6. (hoffmann2025ampylationregulatespld3 pages 26-27): Laura Hoffmann, Eva-Maria Eckl, Marleen Bérouti, Michael Pries, Aron Koller, Charlotte Guhl, Ute A. Hellmich, Veit Hornung, Wei Xiang, Lucas T. Jae, and Pavel Kielkowski. Ampylation regulates pld3 processing. bioRxiv, Jan 2025. URL: https://doi.org/10.1101/2025.01.09.632087, doi:10.1101/2025.01.09.632087. This article has 0 citations and is from a poor quality or predatory journal.

7. (cappel2021quantificationandcharacterization pages 6-7): Cedric Cappel, Adriana Carolina Gonzalez, and Markus Damme. Quantification and characterization of the 5′ exonuclease activity of the lysosomal nuclease pld3 by a novel cell-based assay. Journal of Biological Chemistry, 296:100152, Jan 2021. URL: https://doi.org/10.1074/jbc.ra120.015867, doi:10.1074/jbc.ra120.015867. This article has 25 citations and is from a domain leading peer-reviewed journal.

8. (acker2023phospholipased3degrades pages 9-12): Zoë P. Van Acker, Anika Perdok, Ruben Hellemans, Katherine North, Inge Vorsters, Cedric Cappel, Jonas Dehairs, Johannes V. Swinnen, Ragna Sannerud, Marine Bretou, Markus Damme, and Wim Annaert. Phospholipase d3 degrades mitochondrial dna to regulate nucleotide signaling and app metabolism. Nature Communications, May 2023. URL: https://doi.org/10.1038/s41467-023-38501-w, doi:10.1038/s41467-023-38501-w. This article has 63 citations and is from a highest quality peer-reviewed journal.

9. (nackenoff2021pld3isa pages 4-6): Alex G. Nackenoff, Timothy J. Hohman, Sarah M. Neuner, Carolyn S. Akers, Nicole C. Weitzel, Alena Shostak, Shawn Ferguson, David A. Bennett, Julie A. Schneider, Angela L. Jefferson, Catherine C. Kaczorowski, and Matthew S. Schrag. Pld3 is a neuronal lysosomal phospholipase d associated with β-amyloid plaques and cognitive function in alzheimer’s disease. PLoS Genetics, Aug 2021. URL: https://doi.org/10.1101/746222, doi:10.1101/746222. This article has 52 citations and is from a domain leading peer-reviewed journal.

10. (wang2024phospholipased3regulates pages 1-4): Yongchao Wang, Paige Rieschick, Wilber Romero-Fernandez, Nathan Appelbaum, Cristian Carvajal-Tapia, Alena Shostak, and Matthew Schrag. Phospholipase d3 regulates tfeb/tfe3 metabolism to maintain lysosomal homeostasis. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.26.615214, doi:10.1101/2024.09.26.615214. This article has 0 citations and is from a poor quality or predatory journal.

11. (wang2024phospholipased3regulates pages 4-7): Yongchao Wang, Paige Rieschick, Wilber Romero-Fernandez, Nathan Appelbaum, Cristian Carvajal-Tapia, Alena Shostak, and Matthew Schrag. Phospholipase d3 regulates tfeb/tfe3 metabolism to maintain lysosomal homeostasis. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.26.615214, doi:10.1101/2024.09.26.615214. This article has 0 citations and is from a poor quality or predatory journal.

12. (wang2024phospholipased3regulates pages 10-12): Yongchao Wang, Paige Rieschick, Wilber Romero-Fernandez, Nathan Appelbaum, Cristian Carvajal-Tapia, Alena Shostak, and Matthew Schrag. Phospholipase d3 regulates tfeb/tfe3 metabolism to maintain lysosomal homeostasis. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.26.615214, doi:10.1101/2024.09.26.615214. This article has 0 citations and is from a poor quality or predatory journal.

13. (wang2024phospholipased3regulates pages 24-27): Yongchao Wang, Paige Rieschick, Wilber Romero-Fernandez, Nathan Appelbaum, Cristian Carvajal-Tapia, Alena Shostak, and Matthew Schrag. Phospholipase d3 regulates tfeb/tfe3 metabolism to maintain lysosomal homeostasis. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.26.615214, doi:10.1101/2024.09.26.615214. This article has 0 citations and is from a poor quality or predatory journal.

14. (wang2024phospholipased3regulates pages 27-30): Yongchao Wang, Paige Rieschick, Wilber Romero-Fernandez, Nathan Appelbaum, Cristian Carvajal-Tapia, Alena Shostak, and Matthew Schrag. Phospholipase d3 regulates tfeb/tfe3 metabolism to maintain lysosomal homeostasis. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.26.615214, doi:10.1101/2024.09.26.615214. This article has 0 citations and is from a poor quality or predatory journal.

15. (yuan2022pld3affectsaxonal pages 1-2): Peng Yuan, Mengyang Zhang, Lei Tong, Thomas M. Morse, Robert A. McDougal, Hui Ding, Diane Chan, Yifei Cai, and Jaime Grutzendler. Pld3 affects axonal spheroids and network defects in alzheimer’s disease. Nature, 612:328-337, Nov 2022. URL: https://doi.org/10.1038/s41586-022-05491-6, doi:10.1038/s41586-022-05491-6. This article has 131 citations and is from a highest quality peer-reviewed journal.

Citations

1. roske2024structuralanalysisof pages 1-2
2. yuan2024structuralandmechanistic pages 14-17
3. cappel2021quantificationandcharacterization pages 1-2
4. cappel2021quantificationandcharacterization pages 6-7
5. https://doi.org/10.1093/nar/gkad1114
6. https://doi.org/10.1016/j.str.2024.02.019
7. https://doi.org/10.1074/jbc.ra120.015867;
8. https://doi.org/10.1016/j.cell.2024.09.036
9. https://doi.org/10.1101/2025.01.09.632087
10. https://doi.org/10.1074/jbc.ra120.015867
11. https://doi.org/10.1038/s41467-023-38501-w
12. https://doi.org/10.1101/746222
13. https://doi.org/10.1093/nar/gkad1114;
14. https://doi.org/10.1101/2024.09.26.615214
15. https://doi.org/10.1016/j.str.2024.02.019;
16. https://doi.org/10.1038/s41586-022-05491-6
17. https://doi.org/10.1093/nar/gkad1114,
18. https://doi.org/10.1016/j.str.2024.02.019,
19. https://doi.org/10.1074/jbc.ra120.015867,
20. https://doi.org/10.1016/j.cell.2024.09.036,
21. https://doi.org/10.1101/2025.01.09.632087,
22. https://doi.org/10.1038/s41467-023-38501-w,
23. https://doi.org/10.1101/746222,
24. https://doi.org/10.1101/2024.09.26.615214,
25. https://doi.org/10.1038/s41586-022-05491-6,

provider: openai
model: o3-deep-research-2025-06-26
cached: true
start_time: '2025-11-03T23:38:13.115233'
end_time: '2025-11-03T23:38:13.119391'
duration_seconds: 0.0
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: Q8IV08
gene_symbol: PLD3
provider_config:
timeout: 600
max_retries: 3
parameters:
temperature: 0.1
top_p: 1.0
citation_count: 136

Question

Gene Research for Functional Annotation

Please provide a comprehensive research report on the gene PLD3 (Q8IV08) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

PLD3 (Phospholipase D Family Member 3) – Function, Processes, and Localization

Overview and Key Characteristics

PLD3 is a human gene (UniProt ID Q8IV08) encoding a protein of the phospholipase D superfamily. Despite its name, PLD3 is now recognized not as a conventional phospholipase, but as a lysosomal 5′–3′ exonuclease with a critical role in nucleic acid metabolism (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In other words, PLD3 catalyzes the hydrolysis of phosphodiester bonds in single-stranded nucleic acids from their 5′ end, progressively releasing nucleotide fragments. This activity was historically observed as the classic “spleen acid exonuclease” described in the 1960s (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), but the responsible gene remained unknown for decades. It was only in 2018 that PLD3 was identified as the source of this acidic 5′ exonuclease activity (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The PLD3 protein is highly conserved across mammals (over 90% identical between human, cow, rat, and pig), underscoring its fundamental biological importance (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

PLD3 is broadly expressed in human tissues, with particularly high expression in the brain (pmc.ncbi.nlm.nih.gov). It belongs to a family of six mammalian PLD-like enzymes (PLD1–PLD6) that share a common HxKxxxxD (HKD) catalytic motif (academic.oup.com). Unlike the well-known PLD1 and PLD2 that act as phospholipases hydrolyzing phosphatidylcholine, PLD3’s primary function is nucleolytic. Early predictions and names (e.g. “choline phosphatase 3” or “phosphatidylcholine-hydrolyzing PLD3”) reflected its homology to PLD enzymes (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). However, targeted studies have since shown PLD3 lacks significant phospholipase activity under physiological conditions, and instead cleaves single-stranded DNA and RNA as its main substrate (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Notably, PLD3 can degrade single-stranded RNA with efficiency similar to single-stranded DNA in vitro (academic.oup.com), although DNA appears to be the major physiological substrate in cells (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Structure and Enzymatic Function

The PLD3 protein is synthesized as a type II transmembrane glycoprotein about 490 amino acids in length (pmc.ncbi.nlm.nih.gov). It contains a short N-terminal segment facing the cytosol, a single transmembrane helix (around residues ~40–60), and a large C-terminal domain (~430 amino acids) that resides within the lumen of the endoplasmic reticulum (ER) and later endo-lysosomal compartments (academic.oup.com) (pmc.ncbi.nlm.nih.gov). The luminal domain harbors two tandem HKD motifs characteristic of PLD-family phosphodiesterases (academic.oup.com). (Notably, the second HKD in PLD3 is slightly variant, H→E, but it still contributes to the active site (academic.oup.com).) Crystal structural studies in 2024 confirmed that the luminal domain of human PLD3 adopts the α/β hydrolase fold typical of PLD enzymes and forms homodimers in solution (academic.oup.com) (academic.oup.com). Each PLD3 dimer presents two independent active centers, and structures of PLD3 bound to single-stranded DNA fragments show catalytic pockets accommodating nucleotides (academic.oup.com) (academic.oup.com). These structural insights support a mechanism in which the conserved histidine of the HKD motif acts on the phosphodiester backbone of nucleic acids, cleaving one nucleotide at a time from the 5′ end (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Consistent with this, mutating the critical HKD histidines abolishes PLD3’s nuclease activity (pmc.ncbi.nlm.nih.gov).

Biochemically, PLD3 is a 5′→3′ exonuclease specific for single-stranded nucleic acids. It requires an exposed 5′ terminus to initiate cleavage and has negligible endonuclease or 3′-exonuclease activity (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Optimal activity occurs in the acidic pH range (around pH 5.0–6.0) (pmc.ncbi.nlm.nih.gov), aligning with the enzyme’s lysosomal locale. In vitro assays show that PLD3 cleavage of oligonucleotides yields mainly 3′ mononucleotides and nucleosides as products (pmc.ncbi.nlm.nih.gov). (This indicates that PLD3 hydrolyzes the phosphodiester bond such that the leaving nucleotide retains its 3′ phosphate, similar to classical spleen phosphodiesterase (pmc.ncbi.nlm.nih.gov).) The enzyme is relatively non-sequence-specific, degrading a wide variety of single-stranded DNA sequences and even RNA, although it shows low efficiency on well-paired double-stranded DNA (pmc.ncbi.nlm.nih.gov). Moreover, PLD3 is reported to be non-processive, meaning it may dissociate after releasing each nucleotide or short fragment, akin to the behavior of the historical spleen exonuclease (pmc.ncbi.nlm.nih.gov). This non-processive nature was deduced from early biochemical characterizations and matches the conserved properties observed for PLD3 and its paralog PLD4 (pmc.ncbi.nlm.nih.gov).

It is worth noting that overexpression studies have occasionally reported low levels of phospholipase activity for PLD3 in cell culture (academic.oup.com). For example, one group observed that transfected PLD3 could hydrolyze a phospholipid substrate in COS-7 cells (academic.oup.com). However, such findings are considered experimental artifacts or overexpression-related effects. Current consensus is that PLD3’s physiologic role is as a nuclease, and it does not significantly contribute to lipid phospholipid metabolism in vivo (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This consensus is supported by genetic and biochemical evidence (see below) and has redefined PLD3’s enzyme classification to EC 3.1.16.1 (5′-3′ exonuclease) (www.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Localization, Processing, and Regulation

PLD3 follows the secretory pathway and localizes primarily to acidic endosomal and lysosomal compartments within the cell. After translation in the ER, the type II membrane topology of PLD3 positions its large C-terminal domain in the ER lumen, where it undergoes N-linked glycosylation (pmc.ncbi.nlm.nih.gov). (Multiple N-glycosylation sites are present; for example, Asn-97 is a confirmed glycosylation site (glycosmos.org), and others exist throughout the luminal domain.) Glycosylation is important for proper folding and stability, as is typical for lysosomal enzymes. PLD3 then traffics from the Golgi to endo-lysosomes. Unlike soluble lysosomal hydrolases that use mannose-6-phosphate receptors, PLD3’s membrane-bound nature requires a different targeting mechanism. The cytosolic N-terminus of PLD3 is ubiquitinated, which serves as a lysosomal sorting signal (academic.oup.com). Ubiquitinated PLD3 is recognized by the ESCRT machinery and incorporated into the inward budding vesicles of multivesicular bodies, delivering PLD3 into intra-lysosomal vesicles (academic.oup.com).

Within the lysosome, PLD3 undergoes proteolytic cleavage, separating the luminal catalytic domain (~55 kDa) from the membrane anchor (pmc.ncbi.nlm.nih.gov). This cleavage likely occurs via lysosomal proteases after PLD3 is sequestered into intraluminal vesicles, or at the lysosomal membrane, releasing the soluble C-terminal domain into the lysosomal lumen (academic.oup.com) (pmc.ncbi.nlm.nih.gov). The cleaved luminal fragment is the active enzyme that degrades nucleic acids in the lysosome. Experimental evidence shows that PLD3’s luminal domain is quite stable once processed – it remains as a mature enzyme in lysosomes (pmc.ncbi.nlm.nih.gov). Proper processing is crucial: mutations that disrupt PLD3 trafficking or cleavage can lead to mislocalization or an inactive enzyme. For instance, a disease-associated mutant (L308P) was found to misfold and partially lose lysosomal targeting (academic.oup.com), suggesting that correct folding and cleavage are needed for function.

PLD3 is also subject to unusual post-translational regulations. A recent proteomics study (2024) found that PLD3 can be AMPylated (covalently modified by adenylylation) in cells, and this modification impacted its lysosomal processing (pubmed.ncbi.nlm.nih.gov). Specifically, AMPylation of luminal PLD3 was proposed to reduce its proteolytic cleavage, thereby modulating the amount of active enzyme in lysosomes. Such a regulatory mechanism hints that cells can fine-tune PLD3 activity in response to certain signals – for example, during stress or in certain neurodegenerative conditions where AMPylation levels change (pubmed.ncbi.nlm.nih.gov). While the full biological context of PLD3 AMPylation remains to be explored, this finding highlights that PLD3’s function can be dynamically regulated beyond gene expression alone.

In summary, PLD3 is normally localized to lysosomes (and late endosomes) where its active luminal domain encounters nucleic acid substrates. Microscopy studies confirm that PLD3 co-localizes with lysosomal markers (like LAMP2) in cells (academic.oup.com). Notably, in neurons, PLD3 has been observed accumulating in axonal lysosome-related organelles; for example, PLD3 immunostaining is enriched in neuritic plaques in Alzheimer’s disease (AD) brains (pmc.ncbi.nlm.nih.gov). This localization to pathological protein aggregates likely reflects the buildup of lysosomal vesicles in dystrophic neurites, a common feature of neurodegenerative disease. Overall, the spatial context of PLD3’s activity – within the acidic lumen of degradative organelles – is central to its role in cellular homeostasis.

Biological Roles and Pathways

PLD3’s primary biological role is in the degradation of nucleic acids within lysosomes, which is a crucial part of cellular waste management and innate immune regulation. Any DNA or RNA from phagocytosed material, apoptotic cells, organelle turnover (e.g. from mitophagy), or invasive pathogens must be broken down in lysosomes. PLD3, together with other lysosomal nucleases, ensures this degradation is efficient and complete. In particular, PLD3 acts after initial endonucleases have cut nucleic acids into fragments. For instance, lysosomal RNase T2 cleaves single-stranded RNA into oligonucleotides (academic.oup.com), and DNA-specific DNase II (acid DNase) cuts double-stranded DNA internally. PLD3 then processes the resulting fragments by chewing in from the 5′ ends, yielding mononucleotides (pmc.ncbi.nlm.nih.gov). This sequential teamwork of nucleases ensures that nucleic acid debris is fully destroyed. Consistent with this, cells lacking PLD3 show accumulation of short DNA fragments in endolysosomal compartments (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These undigested fragments can have significant consequences: they can escape or be sensed, leading to inappropriate immune activation (see below).

One of the most critical pathways involving PLD3 is the regulation of endosomal Toll-like receptors (TLRs) that detect nucleic acids. TLR9 recognizes unmethylated DNA (often CpG-rich) and TLR7/8 recognize single-stranded RNA in endosomes. In normal conditions, PLD3 helps limit the availability of immunostimulatory DNA and RNA in endosomes by degrading them. Research in Nature Immunology (2018) demonstrated that murine immune cells deficient in PLD3 (and its close paralog PLD4) had impaired turnover of TLR9 ligands and consequently hyperactive TLR9 signaling (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Purified PLD3/PLD4 enzymes were shown to degrade CpG oligodeoxynucleotides (TLR9 agonists) in vitro, especially those without protective modifications, thereby reducing TLR9 activation (pmc.ncbi.nlm.nih.gov). This indicates PLD3 acts as a negative regulator of DNA-sensing TLR pathways: by destroying DNA ligands, it prevents excessive type I interferon and cytokine responses to self-DNA or chronically present DNA. Indeed, mice lacking both Pld3 and Pld4 develop fatal inflammatory disease early in life. Double-knockout pups exhibited severe liver inflammation and overproduction of inflammatory cytokines, dying within weeks of birth (pmc.ncbi.nlm.nih.gov). This lethal phenotype underscores that at least one of these exonucleases is required to keep innate immune sensors quiescent by disposing of nucleic acid by-products. Even single-gene knockouts have immune consequences: Pld4^-/- mice, for example, showed chronic immune activation reminiscent of macrophage activation syndrome (an inflammatory condition) (pmc.ncbi.nlm.nih.gov). These findings firmly establish PLD3 (and PLD4) as part of the cell’s innate immune homeostasis machinery, functionally analogous to intracellular DNA exonucleases like TREX1 (which works in the cytosol) but operating within lysosomes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Recent research has also identified mitochondrial DNA (mtDNA) as a key endogenous substrate of PLD3, linking PLD3 to the cGAS–STING pathway of innate immunity. A 2023 study in Nature Communications found that loss of PLD3 in neuronal cells led to the accumulation of mtDNA inside lysosomes and its leakage into the cytosol (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Normally, mtDNA released by damaged mitochondria is delivered to lysosomes for degradation. In PLD3-deficient cells, mtDNA was not efficiently degraded, resulting in fragments that escaped into the cytoplasm and activated the cGAS-STING pathway – a cytosolic DNA-sensing mechanism that triggers interferon responses (pmc.ncbi.nlm.nih.gov). Activation of STING in those PLD3-deficient neurons drove a stress response that included enhanced autophagy (as the cell attempts to remove the accumulating material) and altered metabolism (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Intriguingly, this study also connected the overactive STING signaling to changes in processing of amyloid precursor protein (APP), suggesting a bridge between nucleic-acid clearance in lysosomes and neurodegenerative pathways (discussed more below). The cGAS-STING activation in PLD3 knockout models could be partially normalized by reintroducing PLD3 or by pharmacologically inhibiting STING, confirming that the effect was due to aberrant DNA persisting and engaging innate sensors (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In summary, PLD3 serves as a guardian in the lysosome, preventing untimely immune activation by degrading self-DNA (such as mtDNA) and probably foreign nucleic acids (e.g. viral genomic DNA/RNA) that end up in lysosomes during infections.

Beyond immune regulation, PLD3’s nucleolytic function is generally important for cellular clearance processes. For example, during autophagy, cellular components (including nuclei or organelles) are delivered to lysosomes; nucleic acids therein must be broken down. PLD3 deficiency has been associated with defective degradation in autolysosomes, leading to secondary issues like buildup of undigested material. The loss of PLD3 (along with PLD4) in mice causes accumulation of undegraded lysosomal DNA/RNA which continuously stimulates immune sensors, indicating a failure of complete clearance (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). There is also evidence that PLD3 dysfunction can perturb lipid metabolism in lysosomes. Van Acker et al. (2023) observed that human cell models lacking PLD3 had 2–3× higher lysosomal storage lipid accumulation compared to normal cells (pmc.ncbi.nlm.nih.gov). This was attributed to broad lysosomal dyshomeostasis: the backlogged nucleic acids and chronic STING activation might impair lysosome function or gene expression programs (like cholesterol metabolism pathways) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Indeed, PLD3-deficient cells showed changes in cholesterol processing and in the activity of SREBP2 (a cholesterol regulator), linking PLD3 indirectly to lipid homeostasis via lysosomal function (pmc.ncbi.nlm.nih.gov). While the primary role of PLD3 is nucleic acid catabolism, these observations illustrate how its loss can have pleiotropic downstream effects on cellular physiology – reflecting the central role of lysosomes in many metabolic and signaling networks.

Connections to Human Disease and Clinical Insights

Alzheimer’s Disease (AD): PLD3 came to prominence in 2014 when a rare coding variant in PLD3 was reported to be associated with a doubled risk of late-onset Alzheimer’s disease (academic.oup.com). The variant (a missense mutation Val232Met, V232M) was initially found in AD patients more frequently than in healthy elderly controls, and carriers showed worse memory performance (pmc.ncbi.nlm.nih.gov). This discovery prompted intense interest in PLD3 as a potential AD-related gene. However, subsequent genetic studies yielded mixed results – several groups failed to replicate a significant association of common PLD3 variants with AD risk (academic.oup.com). A 2018 meta-analysis concluded that PLD3 variants have at most a modest effect on AD risk (academic.oup.com). The initial risk finding is now viewed as controversial, and some researchers suggest the early results may have been confounded by strong overexpression artifacts in cellular models rather than true genetic causation (academic.oup.com). In essence, the role of PLD3 in AD predisposition remains unproven, and it is not considered a major genetic risk factor at present.

That said, biological studies continue to support a link between PLD3 and AD-related processes. PLD3 is highly expressed in neurons, and its protein product localizes to neuronal lysosomes, which are critical sites for APP processing and Aβ peptide generation (pmc.ncbi.nlm.nih.gov). It has been observed that PLD3 levels are altered in AD brains and that PLD3 accumulates around β-amyloid plaques in the brain (pmc.ncbi.nlm.nih.gov). Experimental overexpression of PLD3 in cell and animal models was reported to reduce levels of full-length APP and Aβ peptides, whereas PLD3 knockdown or loss led to increased Aβ production (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These effects hint that PLD3 might influence how APP is trafficked or degraded in the endolysosomal pathway. The 2023 Nature Communications study provided a more refined explanation: loss of PLD3 causes chronic STING activation and lysosomal stress, which in turn can alter APP metabolism. In PLD3 knockout neuronal cells, the accumulation of APP C-terminal fragments (APP-CTFs, the direct precursors to Aβ) was observed, alongside elevated secretion of Aβ40/42 peptides (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This accumulation was tied to impaired autophagic clearance – essentially, overloaded lysosomes and high STING activity slowed the turnover of APP fragments (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Notably, when STING signaling was pharmacologically inhibited in these PLD3-deficient cells, the abnormal buildup of APP-CTFs was largely rescued (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Furthermore, genetic removal of APP itself in the PLD3-deficient background reduced the excessive autophagy and lysosomal disruptions (pmc.ncbi.nlm.nih.gov), indicating a two-way interplay. These findings outline a novel pathogenic feedback loop: PLD3 dysfunction → mtDNA escape and STING activation → lysosome-autophagy dysfunction → altered APP/Aβ metabolism, which could exacerbate neuronal damage in AD (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). While this is an emerging hypothesis, it aligns with the broader view that endolysosomal health and innate immune activation are important in late-onset AD. Thus, even if PLD3 variants are not a major cause of AD, PLD3 activity (or lack thereof) may influence disease progression or severity by modulating these cellular pathways.

Neurodegeneration and Ataxia: Apart from AD, PLD3 has been investigated in other neurological disorders. A rare mutation in PLD3 (e.g. L308P) was reported in a family with spinocerebellar ataxia (SCA46), suggesting PLD3 as a candidate gene for this dominantly inherited ataxia (academic.oup.com). The proposed mechanism was that this mutation caused PLD3 loss-of-function, leading to neurodegeneration in cerebellar neurons. However, the link between PLD3 and SCA46 is still under debate. Subsequent analyses did not find PLD3 mutations in other SCA patients, and the original family’s genome had other potential culprit genes (academic.oup.com). Researchers pointed out that the L308P variant disrupts PLD3’s normal lysosomal localization and stability (academic.oup.com), which could conceivably contribute to neuronal dysfunction; but definitive proof of causation is lacking. As of 2023, PLD3 is not firmly established as an ataxia gene, though it remains of interest and further cases are being studied to clarify this link (academic.oup.com). What the ataxia report did highlight is that neurons (particularly Purkinje cells in the cerebellum) may be vulnerable to disruptions in lysosomal nucleic acid clearance. If PLD3 function is compromised, accumulating nucleic acids or the resulting inflammation could impair neuronal homeostasis over time.

Autoimmune Disease: Given PLD3’s role in restraining nucleic acid–triggered innate immunity, it is plausible that variations in PLD3 could impact susceptibility to autoimmune or inflammatory diseases. To date, strong human genetic links have been seen with its paralog PLD4 – certain PLD4 variants are associated with systemic lupus erythematosus and rheumatoid arthritis (academic.oup.com). For PLD3, no common variant with a large effect has been definitively tied to autoimmunity, but research is ongoing. One study noted that PLD3 is broadly expressed (including in some immune cells), so it may compensate for PLD4 except in certain contexts (academic.oup.com). In mouse models, as mentioned, the absence of PLD3/4 leads to interferon-driven inflammation resembling autoimmune syndromes, reinforcing the idea that defects in lysosomal nucleic acid processing can precipitate autoimmune pathology (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

From a clinical perspective, PLD3’s involvement in these pathways makes it an intriguing therapeutic target or biomarker. For example, boosting PLD3 activity might help “clean up” DNA in conditions where auto-reactive inflammation is a problem (like lupus or Aicardi-Goutières syndrome, which involve DNA sensing). Conversely, inhibiting PLD3 in a controlled way could potentially enhance vaccine responses or anti-tumor immunity by allowing more DNA-based activation of TLR9/STING – though with the risk of inflammation. As of now, no drugs specifically target PLD3, but experts have suggested that modulating PLD3 could be immunomodulatory (academic.oup.com) (academic.oup.com). The recent structural resolution of PLD3 may facilitate structure-guided design of small molecules that adjust its activity (academic.oup.com) (academic.oup.com). Additionally, PLD3 levels or mutation status might serve as a biomarker in neurodegenerative disease research. For instance, reduced PLD3 expression or activity could indicate a propensity for accumulation of lysosomal DNA and ensuing neuroinflammation, potentially correlating with disease progression in AD (some studies have reported epigenetic changes reducing PLD3 expression in AD brains (pmc.ncbi.nlm.nih.gov)).

Expert Commentary and Future Directions

Researchers now broadly view PLD3 as a lysosomal “housekeeping” enzyme that safeguards cellular homeostasis. The discovery of its nuclease function answered a long-standing question about the identity of acidic spleen exonuclease (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Expert opinions emphasize that PLD3 (and PLD4) form an important parallel to other nucleic acid control mechanisms (like TREX1 in the cytosol or DNase II in lysosomes) to prevent harmful accumulation of DNA/RNA. As immunologist Kate Fitzgerald commented in 2018, the fact that Pld3/4 double-knockout mice succumb to inflammatory disease underscores how crucial this pathway is to avoid self-DNA sensing (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Immunology experts have noted that these findings broaden our understanding of innate immunity, revealing the lysosome as not just a degradation center but also a regulatory hub where insufficient degradation can tip off immune receptors (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Neurologists studying Alzheimer’s disease have also taken interest. While the genetic link between PLD3 and AD is debated (academic.oup.com), (academic.oup.com), neurobiologists like R. Cruchaga (who first reported the PLD3-AD variant) suggest that even if PLD3 variants are rare, the lysosomal processes it participates in are likely part of AD pathology (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The latest research supports a view that age-related decline in lysosomal nuclease function or minor inherited reductions in PLD3 activity could contribute to late-life proteinopathies by aggravating inflammation and proteostasis defects (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This aligns with a growing consensus that enhancement of lysosomal function is broadly beneficial in neurodegenerative diseases. Some experts speculate that upregulating PLD3 (for instance via small molecules or gene therapy) in the brain might improve clearance of neuronal waste and mitigate neuroinflammation, though this remains to be tested.

On the structural biology front, scientists Aleksandar Bijelić and Peter Macheroux (who published one of the 2024 PLD3 structures) highlighted that the enzyme’s dimeric arrangement and substrate-bound conformation provide “a molecular basis for understanding its normal and pathological functions” (pmc.ncbi.nlm.nih.gov) (academic.oup.com). Important questions for the future include determining how PLD3 selects its substrates (e.g. any preference for DNA vs RNA or sequence motifs), and how it cooperates with other lysosomal nucleases. There is also interest in discovering regulatory partners: for example, does PLD3 interact with lysosomal membrane proteins or require cofactors for full activity? The newly observed AMPylation modification points to regulatory crosstalk with cellular signaling pathways (pubmed.ncbi.nlm.nih.gov). Since AMPylation often occurs under ER stress or in specific developmental contexts, it raises the possibility that PLD3’s activity could be dialed down when cells are under stress, perhaps to prioritize other pathways or due to changes in lysosomal pH.

In conclusion, PLD3 serves as a critical lysosomal nuclease, maintaining a balance between waste degradation and immune surveillance. It illustrates how finely tuned our cells must be in handling self-DNA: too little cleanup can trigger inflammation, while proper function prevents unwarranted immune responses. Ongoing research in 2023–2024 has not only clarified PLD3’s enzymatic function and 3D structure, but also connected it to complex disease pathways in neurodegeneration and immunity. As we advance, targeting the PLD3 pathway could emerge as a novel strategy to modulate innate immunity or to bolster lysosomal health in age-related diseases. The precise role of PLD3 in human health and disease will be further illuminated by future studies, but it is already clear that this once-mysterious “phospholipase D” family member is, in reality, an essential nuclease at the intersection of metabolism, immunity, and neurobiology.

References:

1. Gavin AL et al. (2018). Nat. Immunol. 19(9):942–953. DOI: 10.1038/s41590-018-0179-y — Identified PLD3 and PLD4 as lysosomal 5′ exonucleases that degrade nucleic acids and regulate TLR9 signaling (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
2. Roske Y et al. (2024). Nucleic Acids Res. 52(1):370–384. DOI: 10.1093/nar/gkad1135 — Reported crystal structures of human PLD3, confirming its dimeric phosphodiesterase fold and ssDNA-bound active site (academic.oup.com) (academic.oup.com).
3. Van Acker ZP et al. (2023). Nat. Commun. 14:2847 (24 May 2023). DOI: 10.1038/s41467-023-38501-w — Demonstrated that PLD3 degrades mitochondrial DNA, linking PLD3 loss to cGAS-STING activation and altered APP (amyloid precursor protein) processing (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
4. Cruchaga C et al. (2014). Nature 513(7518):436–440. DOI: 10.1038/nature13725 — Initial report of a PLD3 V232M variant associated with increased risk of Alzheimer’s disease (academic.oup.com) (subsequent studies provided mixed evidence (academic.oup.com)).
5. Gonzalez AC et al. (2018). Brain 141(11):e78. DOI: 10.1093/brain/awy252 — Discussion on PLD3 in spinocerebellar ataxia (SCA46), highlighting lysosomal enzyme function and debating causality of PLD3 mutations in ataxia (academic.oup.com) (academic.oup.com).

Citations

1. AnnotationURLCitation(end_index=571, start_index=391, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=were%20presumed%20to%20be%20phospholipases%2C,required%20to%20regulate%20inflammatory%20cytokine')
2. AnnotationURLCitation(end_index=713, start_index=572, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=but%20not%203%E2%80%B2,ends%20and%20was%20unaffected%20by')
3. AnnotationURLCitation(end_index=1111, start_index=987, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=We%20find%20that%20PLD3%20and,processive')
4. AnnotationURLCitation(end_index=1255, start_index=1112, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=and%20nucleosides%20as%20does%20the,The%20similarities%20in')
5. AnnotationURLCitation(end_index=1553, start_index=1414, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=expressed,and%20diminished%20turnover%20of%2C%20ligands')
6. AnnotationURLCitation(end_index=1695, start_index=1554, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=but%20not%203%E2%80%B2,ends%20and%20was%20unaffected%20by')
7. AnnotationURLCitation(end_index=1979, start_index=1855, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=We%20find%20that%20PLD3%20and,processive')
8. AnnotationURLCitation(end_index=2123, start_index=1980, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=and%20nucleosides%20as%20does%20the,The%20similarities%20in')
9. AnnotationURLCitation(end_index=2369, start_index=2218, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=match%20at%20L80%20regulation,is%20highly%20expressed%20in%20brain')
10. AnnotationURLCitation(end_index=2669, start_index=2495, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=5%E2%80%B2%20exonucleases%20PLD3%20or%20PLD4,linear%20sequences%20containing%20the%20amino')
11. AnnotationURLCitation(end_index=3072, start_index=2946, title='PLD3 phospholipase D family member 3 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/23646#:~:text=Names%20%28S%2CS%29,hydrolyzing%20phospholipase%20D3')
12. AnnotationURLCitation(end_index=3191, start_index=3073, title='PLD3 phospholipase D family member 3 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/23646#:~:text=%28S%2CS%29,hydrolyzing%20phospholipase%20D3')
13. AnnotationURLCitation(end_index=3533, start_index=3392, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=but%20not%203%E2%80%B2,ends%20and%20was%20unaffected%20by')
14. AnnotationURLCitation(end_index=3653, start_index=3534, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=match%20at%20L280%20exonuclease,The')
15. AnnotationURLCitation(end_index=3943, start_index=3757, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=%E2%80%98spleen%20exonuclease%E2%80%99%20was%20identified%20as,fact%2C%20PLD3%20cleaves%20ssRNA%20with')
16. AnnotationURLCitation(end_index=4141, start_index=4015, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=match%20at%20L225%20from%20PLD3,We%20next')
17. AnnotationURLCitation(end_index=4248, start_index=4142, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=from%20PLD3,We%20next')
18. AnnotationURLCitation(end_index=4573, start_index=4398, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=variants%2C%20including%20M6R%2C%20K228R%2C%20V232M%2C,considered%20to%20be%20the%20mature')
19. AnnotationURLCitation(end_index=5004, start_index=4840, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=similar%20high%20efficiency%20to%20ssDNA,type%20II%20topology%20determines%20the')
20. AnnotationURLCitation(end_index=5180, start_index=5005, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=variants%2C%20including%20M6R%2C%20K228R%2C%20V232M%2C,considered%20to%20be%20the%20mature')
21. AnnotationURLCitation(end_index=5453, start_index=5279, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=5%E2%80%B2%20exonucleases%20PLD3%20or%20PLD4,linear%20sequences%20containing%20the%20amino')
22. AnnotationURLCitation(end_index=5726, start_index=5558, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=biochemical%20mechanism%20and%20an%20H,linear%20sequences%20containing%20the%20amino')
23. AnnotationURLCitation(end_index=6066, start_index=5910, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=domain%20of%20human%20PLD3%20in,in%20the%20catalytic%20center%20provides')
24. AnnotationURLCitation(end_index=6223, start_index=6067, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=domain%20of%20human%20PLD3%20in,in%20the%20catalytic%20center%20provides')
25. AnnotationURLCitation(end_index=6549, start_index=6393, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=domain%20of%20human%20PLD3%20in,in%20the%20catalytic%20center%20provides')
26. AnnotationURLCitation(end_index=6718, start_index=6550, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=domain%20of%20PLD3%20as%20an,designing%20immunomodulatory%20drugs%20targeting%20PLD3')
27. AnnotationURLCitation(end_index=7061, start_index=6920, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=but%20not%203%E2%80%B2,ends%20and%20was%20unaffected%20by')
28. AnnotationURLCitation(end_index=7181, start_index=7062, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=match%20at%20L280%20exonuclease,The')
29. AnnotationURLCitation(end_index=7425, start_index=7277, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=match%20at%20L232%20but%20not,ends%20and%20was%20unaffected%20by')
30. AnnotationURLCitation(end_index=7785, start_index=7637, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=match%20at%20L232%20but%20not,ends%20and%20was%20unaffected%20by')
31. AnnotationURLCitation(end_index=7905, start_index=7786, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=match%20at%20L280%20exonuclease,The')
32. AnnotationURLCitation(end_index=8154, start_index=7974, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=spleen%20phosphodiesterase%20II%20%28spleen%20exonuclease%29,and%20PLD4%20are%20abbreviated%20as')
33. AnnotationURLCitation(end_index=8445, start_index=8326, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=match%20at%20L280%20exonuclease,The')
34. AnnotationURLCitation(end_index=8732, start_index=8613, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=match%20at%20L280%20exonuclease,The')
35. AnnotationURLCitation(end_index=9082, start_index=8923, title='Quantification and characterization of the 5′ exonuclease activity of the lysosomal nuclease PLD3 by a novel cell-based assay - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7857491/#:~:text=lysosomal%20nuclease%20PLD3%20by%20a,This%20enzyme%20was%20later%20assigned')
36. AnnotationURLCitation(end_index=9396, start_index=9272, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=We%20find%20that%20PLD3%20and,processive')
37. AnnotationURLCitation(end_index=9678, start_index=9554, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=We%20find%20that%20PLD3%20and,processive')
38. AnnotationURLCitation(end_index=9964, start_index=9818, title='Reply: PLD3 and spinocerebellar ataxia | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/141/11/e79/5127750#:~:text=Reply%3A%20PLD3%20and%20spinocerebellar%20ataxia,7%20cells')
39. AnnotationURLCitation(end_index=10222, start_index=10076, title='Reply: PLD3 and spinocerebellar ataxia | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/141/11/e79/5127750#:~:text=Reply%3A%20PLD3%20and%20spinocerebellar%20ataxia,7%20cells')
40. AnnotationURLCitation(end_index=10654, start_index=10474, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=were%20presumed%20to%20be%20phospholipases%2C,required%20to%20regulate%20inflammatory%20cytokine')
41. AnnotationURLCitation(end_index=10796, start_index=10655, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=but%20not%203%E2%80%B2,ends%20and%20was%20unaffected%20by')
42. AnnotationURLCitation(end_index=11078, start_index=10956, title='PLD3 phospholipase D family member 3 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/23646#:~:text=hindIII%20K4L%20homolog%20phosphatidylcholine,D3')
43. AnnotationURLCitation(end_index=11242, start_index=11079, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=the%20activity%20previously%20described%20as,a%20positive%20control%20using%20a')
44. AnnotationURLCitation(end_index=11762, start_index=11587, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=variants%2C%20including%20M6R%2C%20K228R%2C%20V232M%2C,considered%20to%20be%20the%20mature')
45. AnnotationURLCitation(end_index=11961, start_index=11863, title='GlyCosmos Portal', type='url_citation', url='https://glycosmos.org/glycoproteins/Q8IV08#:~:text=GlyCosmos%20Portal%20,linked')
46. AnnotationURLCitation(end_index=12542, start_index=12408, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=match%20at%20L381%20lysosome,This%20genetic%20link')
47. AnnotationURLCitation(end_index=12856, start_index=12722, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=match%20at%20L381%20lysosome,This%20genetic%20link')
48. AnnotationURLCitation(end_index=13176, start_index=13001, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=variants%2C%20including%20M6R%2C%20K228R%2C%20V232M%2C,considered%20to%20be%20the%20mature')
49. AnnotationURLCitation(end_index=13541, start_index=13383, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=match%20at%20L376%20similar%20high,type%20II%20topology%20determines%20the')
50. AnnotationURLCitation(end_index=13717, start_index=13542, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=variants%2C%20including%20M6R%2C%20K228R%2C%20V232M%2C,considered%20to%20be%20the%20mature')
51. AnnotationURLCitation(end_index=14124, start_index=13949, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=variants%2C%20including%20M6R%2C%20K228R%2C%20V232M%2C,considered%20to%20be%20the%20mature')
52. AnnotationURLCitation(end_index=14507, start_index=14369, title='PLD3 and spinocerebellar ataxia | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/141/11/e78/5127752#:~:text=Nibbeling%20et%20al.%20used%20GFP,mutant%20protein')
53. AnnotationURLCitation(end_index=14997, start_index=14824, title="AMPylation Regulates 5'-3' Exonuclease PLD3 Processing - PubMed", type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/40816421/#:~:text=Keywords%3A%20AMPylation%3B%20PLD3%3B%20chemical%20proteomics%3B,translational%20modifications')
54. AnnotationURLCitation(end_index=15468, start_index=15361, title="AMPylation Regulates 5'-3' Exonuclease PLD3 Processing - PubMed", type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/40816421/#:~:text=neurodegenerative%20diseases')
55. AnnotationURLCitation(end_index=16083, start_index=15897, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=%E2%80%98spleen%20exonuclease%E2%80%99%20was%20identified%20as,fact%2C%20PLD3%20cleaves%20ssRNA%20with')
56. AnnotationURLCitation(end_index=16457, start_index=16289, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=dysregulated%20APP%20processing%20and%20an,27%2C37%7D.%20In%20contrast%2C%20however')
57. AnnotationURLCitation(end_index=17612, start_index=17426, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=%E2%80%98spleen%20exonuclease%E2%80%99%20was%20identified%20as,fact%2C%20PLD3%20cleaves%20ssRNA%20with')
58. AnnotationURLCitation(end_index=17910, start_index=17791, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=match%20at%20L280%20exonuclease,The')
59. AnnotationURLCitation(end_index=18249, start_index=18123, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=match%20at%20L225%20from%20PLD3,We%20next')
60. AnnotationURLCitation(end_index=18356, start_index=18250, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=from%20PLD3,We%20next')
61. AnnotationURLCitation(end_index=19258, start_index=19089, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=deficient%20in%20both%20PLD3%20and,required%20to%20regulate%20inflammatory%20cytokine')
62. AnnotationURLCitation(end_index=19404, start_index=19259, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=match%20at%20L443%20%28Fig,similar%20in%20human%20and%20mouse')
63. AnnotationURLCitation(end_index=19746, start_index=19595, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=PLD3%20and%20PLD4%20can%20degrade,agonists%20of%20TLR9%20in%20vitro')
64. AnnotationURLCitation(end_index=20361, start_index=20181, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=were%20presumed%20to%20be%20phospholipases%2C,required%20to%20regulate%20inflammatory%20cytokine')
65. AnnotationURLCitation(end_index=20850, start_index=20721, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=Trex1%20exonuclease%20in%20the%20cytoplasm,42')
66. AnnotationURLCitation(end_index=21216, start_index=21091, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=%28Fig,similar%20in%20human%20and%20mouse')
67. AnnotationURLCitation(end_index=21346, start_index=21217, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=Trex1%20exonuclease%20in%20the%20cytoplasm,42')
68. AnnotationURLCitation(end_index=21812, start_index=21678, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=PLD3,an%20altered%20PLD3%20exonuclease%20activity')
69. AnnotationURLCitation(end_index=21965, start_index=21813, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=activator%20of%20STING,an%20altered%20PLD3%20exonuclease%20activity')
70. AnnotationURLCitation(end_index=22421, start_index=22287, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=PLD3,an%20altered%20PLD3%20exonuclease%20activity')
71. AnnotationURLCitation(end_index=22738, start_index=22614, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=amyloid%20precursor%20C,talks%20through')
72. AnnotationURLCitation(end_index=22877, start_index=22739, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=,reminiscent%20features%20of%20AD%20neuropathogenesis')
73. AnnotationURLCitation(end_index=23509, start_index=23370, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=match%20at%20L39%20amyloid%20precursor,talks%20through')
74. AnnotationURLCitation(end_index=23637, start_index=23510, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=cGAS,dysfunction%20with%20APP%20metabolism')
75. AnnotationURLCitation(end_index=24622, start_index=24483, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=expressed,and%20diminished%20turnover%20of%2C%20ligands')
76. AnnotationURLCitation(end_index=24768, start_index=24623, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=match%20at%20L443%20%28Fig,similar%20in%20human%20and%20mouse')
77. AnnotationURLCitation(end_index=25166, start_index=25011, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=match%20at%20L414%20and%20xV232M,up%20is%20primarily%20attributed%20to')
78. AnnotationURLCitation(end_index=25517, start_index=25379, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=,reminiscent%20features%20of%20AD%20neuropathogenesis')
79. AnnotationURLCitation(end_index=25699, start_index=25518, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=xV232M%E2%80%94%C2%A0over%20t%E2%80%89%3D%E2%80%89125%E2%80%89s%29,i%20Quantification%20of%20the')
80. AnnotationURLCitation(end_index=26055, start_index=25896, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=match%20at%20L725%20and%20V232M,activated%20SREBP2%20over%20the%20inactive')
81. AnnotationURLCitation(end_index=26708, start_index=26549, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=double%20the%20risk%20of%20developing,cell%20lines%20and%20tissues%2C%20the')
82. AnnotationURLCitation(end_index=27027, start_index=26893, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=PLD3%2C%20the%20V232M%20SNP%20is,33%2C34%7D.%20In')
83. AnnotationURLCitation(end_index=27427, start_index=27268, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=double%20the%20risk%20of%20developing,cell%20lines%20and%20tissues%2C%20the')
84. AnnotationURLCitation(end_index=27678, start_index=27519, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=double%20the%20risk%20of%20developing,cell%20lines%20and%20tissues%2C%20the')
85. AnnotationURLCitation(end_index=28074, start_index=27900, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=and%20extracellular%20A%CE%B242%20and%20A%CE%B240,as%20an%20Alzheimer%27s%20disease%20risk')
86. AnnotationURLCitation(end_index=28659, start_index=28478, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=match%20at%20L64%20precursor%20protein,concentration%2C%20redox%20requirements%2C%20and%20acidic')
87. AnnotationURLCitation(end_index=28956, start_index=28792, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=match%20at%20L132%20dysregulated%20APP,27%2C37%7D.%20In%20contrast%2C%20however')
88. AnnotationURLCitation(end_index=29284, start_index=29152, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=regulation,is%20highly%20expressed%20in%20brain')
89. AnnotationURLCitation(end_index=29453, start_index=29285, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=dysregulated%20APP%20processing%20and%20an,27%2C37%7D.%20In%20contrast%2C%20however')
90. AnnotationURLCitation(end_index=30066, start_index=29928, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=,reminiscent%20features%20of%20AD%20neuropathogenesis')
91. AnnotationURLCitation(end_index=30227, start_index=30067, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=altered%20APP%20proteolysis,secreted%20A%CE%B2%20peptides%20were%20elevated')
92. AnnotationURLCitation(end_index=30517, start_index=30386, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=species,observed%20in%20neuronal%20models%20of')
93. AnnotationURLCitation(end_index=30667, start_index=30518, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=match%20at%20L633%20rather%20than,%E2%88%92%2F%E2%88%92%7D%20and')
94. AnnotationURLCitation(end_index=31003, start_index=30815, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=match%20at%20L642%20xV232M%20cells,positive%20compartments%20%28Fig.%C2%A06g%29.%20Prolonged%20exposure')
95. AnnotationURLCitation(end_index=31193, start_index=31004, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=xV232M%20cells%20compared%20to%20Wt,positive%20compartments%20%28Fig.%C2%A06g%29.%20Prolonged%20exposure')
96. AnnotationURLCitation(end_index=31456, start_index=31329, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=PLD3,observed%20a%20restoration%20of%20the')
97. AnnotationURLCitation(end_index=31837, start_index=31713, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=amyloid%20precursor%20C,talks%20through')
98. AnnotationURLCitation(end_index=31976, start_index=31838, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=,reminiscent%20features%20of%20AD%20neuropathogenesis')
99. AnnotationURLCitation(end_index=32714, start_index=32599, title='PLD3 and spinocerebellar ataxia | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/141/11/e78/5127752#:~:text=phospholipase%20D3%29,Gavin')
100. AnnotationURLCitation(end_index=33217, start_index=33046, title='PLD3 and spinocerebellar ataxia | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/141/11/e78/5127752#:~:text=match%20at%20L320%20analysis%20challenges,of%20PLD3%20in%20spinocerebellar%20ataxia')
101. AnnotationURLCitation(end_index=33447, start_index=33326, title='PLD3 and spinocerebellar ataxia | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/141/11/e78/5127752#:~:text=suggested%20loss,causative%20gene')
102. AnnotationURLCitation(end_index=33879, start_index=33708, title='PLD3 and spinocerebellar ataxia | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/141/11/e78/5127752#:~:text=match%20at%20L320%20analysis%20challenges,of%20PLD3%20in%20spinocerebellar%20ataxia')
103. AnnotationURLCitation(end_index=34692, start_index=34568, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=match%20at%20L386%20PLD3%20has,In%20vivo')
104. AnnotationURLCitation(end_index=35073, start_index=34949, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=match%20at%20L386%20PLD3%20has,In%20vivo')
105. AnnotationURLCitation(end_index=35493, start_index=35313, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=were%20presumed%20to%20be%20phospholipases%2C,required%20to%20regulate%20inflammatory%20cytokine')
106. AnnotationURLCitation(end_index=35623, start_index=35494, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=Trex1%20exonuclease%20in%20the%20cytoplasm,42')
107. AnnotationURLCitation(end_index=36404, start_index=36277, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=immunomodulatory%20drugs%20targeting%20PLD3')
108. AnnotationURLCitation(end_index=36573, start_index=36405, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=domain%20of%20PLD3%20as%20an,designing%20immunomodulatory%20drugs%20targeting%20PLD3')
109. AnnotationURLCitation(end_index=36855, start_index=36699, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=domain%20of%20human%20PLD3%20in,in%20the%20catalytic%20center%20provides')
110. AnnotationURLCitation(end_index=37024, start_index=36856, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=domain%20of%20PLD3%20as%20an,designing%20immunomodulatory%20drugs%20targeting%20PLD3')
111. AnnotationURLCitation(end_index=37543, start_index=37420, title='PLD3 epigenetic changes in the hippocampus of Alzheimer’s disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6134774/#:~:text=PLD3%20epigenetic%20changes%20in%20the,')
112. AnnotationURLCitation(end_index=37966, start_index=37827, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=expressed,and%20diminished%20turnover%20of%2C%20ligands')
113. AnnotationURLCitation(end_index=38091, start_index=37967, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=We%20find%20that%20PLD3%20and,processive')
114. AnnotationURLCitation(end_index=38671, start_index=38502, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=deficient%20in%20both%20PLD3%20and,required%20to%20regulate%20inflammatory%20cytokine')
115. AnnotationURLCitation(end_index=38817, start_index=38672, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=match%20at%20L443%20%28Fig,similar%20in%20human%20and%20mouse')
116. AnnotationURLCitation(end_index=39202, start_index=39057, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=match%20at%20L443%20%28Fig,similar%20in%20human%20and%20mouse')
117. AnnotationURLCitation(end_index=39328, start_index=39203, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=%28Fig,similar%20in%20human%20and%20mouse')
118. AnnotationURLCitation(end_index=39613, start_index=39454, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=double%20the%20risk%20of%20developing,cell%20lines%20and%20tissues%2C%20the')
119. AnnotationURLCitation(end_index=39789, start_index=39615, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=and%20extracellular%20A%CE%B242%20and%20A%CE%B240,as%20an%20Alzheimer%27s%20disease%20risk')
120. AnnotationURLCitation(end_index=40152, start_index=39987, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=precursor%20protein%20,concentration%2C%20redox%20requirements%2C%20and%20acidic')
121. AnnotationURLCitation(end_index=40291, start_index=40153, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=,reminiscent%20features%20of%20AD%20neuropathogenesis')
122. AnnotationURLCitation(end_index=40693, start_index=40535, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=match%20at%20L43%20feedforward%20loops,demise%20as%20observed%20in%20LOAD')
123. AnnotationURLCitation(end_index=40832, start_index=40694, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=,reminiscent%20features%20of%20AD%20neuropathogenesis')
124. AnnotationURLCitation(end_index=41612, start_index=41485, title="Structure of human phospholipase D3, a single‐strand exonuclease associated with Alzheimer's disease - PMC", type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11653683/#:~:text=Skip%20to%20main%20content%20NewTry,Author')
125. AnnotationURLCitation(end_index=41769, start_index=41613, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=domain%20of%20human%20PLD3%20in,in%20the%20catalytic%20center%20provides')
126. AnnotationURLCitation(end_index=42425, start_index=42252, title="AMPylation Regulates 5'-3' Exonuclease PLD3 Processing - PubMed", type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/40816421/#:~:text=Keywords%3A%20AMPylation%3B%20PLD3%3B%20chemical%20proteomics%3B,translational%20modifications')
127. AnnotationURLCitation(end_index=44032, start_index=43852, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=were%20presumed%20to%20be%20phospholipases%2C,required%20to%20regulate%20inflammatory%20cytokine')
128. AnnotationURLCitation(end_index=44162, start_index=44033, title='PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6105523/#:~:text=Trex1%20exonuclease%20in%20the%20cytoplasm,42')
129. AnnotationURLCitation(end_index=44537, start_index=44381, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=domain%20of%20human%20PLD3%20in,in%20the%20catalytic%20center%20provides')
130. AnnotationURLCitation(end_index=44724, start_index=44538, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=%E2%80%98spleen%20exonuclease%E2%80%99%20was%20identified%20as,fact%2C%20PLD3%20cleaves%20ssRNA%20with')
131. AnnotationURLCitation(end_index=45153, start_index=44988, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=precursor%20protein%20,concentration%2C%20redox%20requirements%2C%20and%20acidic')
132. AnnotationURLCitation(end_index=45288, start_index=45154, title='Phospholipase D3 degrades mitochondrial DNA to regulate nucleotide signaling and APP metabolism - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10209153/#:~:text=PLD3,an%20altered%20PLD3%20exonuclease%20activity')
133. AnnotationURLCitation(end_index=45636, start_index=45477, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=double%20the%20risk%20of%20developing,cell%20lines%20and%20tissues%2C%20the')
134. AnnotationURLCitation(end_index=45840, start_index=45681, title='Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation | Nucleic Acids Research | Oxford Academic', type='url_citation', url='https://academic.oup.com/nar/article/52/1/370/7442542#:~:text=double%20the%20risk%20of%20developing,cell%20lines%20and%20tissues%2C%20the')
135. AnnotationURLCitation(end_index=46191, start_index=46076, title='PLD3 and spinocerebellar ataxia | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/141/11/e78/5127752#:~:text=phospholipase%20D3%29,Gavin')
136. AnnotationURLCitation(end_index=46363, start_index=46192, title='PLD3 and spinocerebellar ataxia | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/141/11/e78/5127752#:~:text=match%20at%20L320%20analysis%20challenges,of%20PLD3%20in%20spinocerebellar%20ataxia')